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Introduction

Before beginning e.ny discussion on the management
of pneumonia, the character of the disease itself should
be set forth.

It has long been known that pneumonia

is an acute infectious disease involving one or more
lobes of the lungs.

In the majority of cases it IB

caused by the pneumococcus organism.

Clinically, the

disease is characterized by chills, fever, chest pain,
cough, dyspnea, general malaise , and rusty or bloody
sputum.

The disease runs a courBe of 7 to 10 days and

usually ends abruptly by~risis"; i.e., a sudden drop
in temperature, in favorable cases.
Present day therapy with the sulfonamide drugs
has changed this clinical picture .

Now , in cases that

respond to sulfon&~ide therapy, the temperature falls
by lysis within 24 to 48 hours following the instigation of chemotherapy.

The patient shows marks d clinical

improvement in 48 hours and the characteristic clinical
features of this disease are greatly reduced in
severity .

However , the course of the pneumonic process

in the lung~

not appreciably shortened .

Our new era of chemotherapy has indeed simplified
the management of pneumonia .

-i-

Literally, all the physician

need do is to prescribe a tablet which is to be taken
every four hours .

However, t h is simplicity should not

lull the phy sician into a false sense of security .

It

must be remembered that pneumonia is still a medical
emergency that requires prompt therapy .

Also to be

kept in mind is the fact that the present · members of
the sulfonamide group are not a

11

cure all 11 and their use

at times produces untoward reactions in the patient for
which one must diligently watch .
This thesis was written vi th the express purpose
in mind of eva l uating the comparative merits of serum
and chemotherapy in the treatment of p~eumonia .
is hoped that in the perusal of this

pi:p

It

er , the reader

will carefully note the mortality rates with each
specific form of therapy as they are a guide to the value
of the a g ents used .

It is the opinion of this writer

that the case fatality rates are the best indices for
determining the relative effectiveness of various therapeutic agents and therefore they are carefully presented .
Since chemotherapy is

of paramount importance

in the present day management of pneumonia , a major
part of this thesis will be concerned specifically
with the sulfonamide drugs .

Much material concerning

these drugs is too recent to be found in any text book .

- ii -

The writer has , therefore, tried to bring together
what he considered to be the most valuab le references
in current literature with the purpose of po inting out
the consensus of opinion of present day investigators
regarding all of the sulfonamide drugs which are considered important in the treatrrent of pneumonia .
In the writing of this pap er, the author ra s
considered the pneumonias as a group of specific
infectious disea ses caused by a variety of bacteria .
The management of pneumonia , as taken up in the following pages, includes all of the different forms and
types of the disease .

II

-iii- ·

Histori of Pneumonia Therapz

It is always of interest to compare the past
with the present and tr y to find what of the old has
been retained and what has been discarded.
ry of a subject warrants itself.

Thus a histo-

It is the object of

this history to show the trends and methods used in the
management and treatment of pneumonia.

We shall find as

Conrad (2) said, "that as in different periods the conception of the disease has -varied so has the treatment
varied, the pendulum of medical opinion swinging widely."
Garland (1) very aptly divided the history of
the treatment of pneumonia into six categorical periods
as follows:
1.
2.
3.
4.
5.
6.

The
The
The
The
The
The

depleting period
supportive period
expectant period
antipyretic period
antiseptic period
symptomatic period

As a result of the advent of serum and chemotherapy
since the beginning of this century, we can now add a
seventh specific period or method to this outline.
These methods listed truly represent fashions in treatment which were followed according to the opinions of
the medical leaders.
Although pneumonia was known to Hippocrates
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(460-370 B.C.) and evidently first described by him and

other members of the Greek school the disease must have
existed long before his time for Ruffer, according to
Howard (3) found and demonstrated a gram-positive
pneumococcus in a consolidated lung of a mummy which
Heffron (4) states was of a dynasty extant from 1250
1000 B. C.

to

It is, therefore, possible that pneumonia

was known and treated before the time of Hippocrates .
Hippocrates spoke often of peripneumonia and
other pulmonary infections and thought he could locate
the seat and extent of the local inflammation by the
charact eristics of the coating upon the patient's tongue.
It was also his idea that the disease was caused by
drinking stagnant water.6)The methods of treatment
prevalent in the fifth century before Christ are very
well described by Hippocrates.

Major (6) in his

"Classic Descriptions of Disease" quotes Hippocrates, who
in describing the regimen in acute diseases wrote concerning peripneumonia and pleuritic affections that:
"If the fever be acute, and if there be
pains on either side, or in both, and if expiration be attended with pain, if cough be present,
and the sputa expectorated be of a blond or
livid color, or likewise thin, frothy, and florid,
or having any other character different from the
common, in such a case the physician should proceed thus; if the pain pass upward to the clavicle,
or the breast, or the arm, the inner vein in the
arm should be opened on the side affected, and
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blood abstracted according to the habit,
age, and color of the p:i. tient, and the season
of the year, and that largely and boldly,
if the pain be acute, so as to bring on
deliquium animi, and afterwards a clyster
is to be given. But if the pain be below
the chest, and if ver y intense, purge the
bowels gently in such an attack of pleurisy,
and during the act of purging give nothing;
but after the purging give oxymel. The medicine is to be administered on the fourth day;
on the first thr.ee days after the commencement,
a clyster should be given, and if it does not
relieve the patient, he should be gently purged,
but he is to be watched until the fever goes
off, and till the seventh day; then if he appears
to be free from danger, give him son:r9 unstrained
ptisan, in a small quantity, and thin at first,
mixing it v.d.th honey. If the expectoration b!=)
easy and the breathing free, if his sides be
free of pain, and if the fever be gone, he may
take the ptisan thicker, and in larger quantity,
twice a day. But if he does not progress
favorably, he must get less of the drink, and
of the draught, v.hich should be thin, and only
given once a day, at whatever is judged to be
the most favorable time; this you will ascertain
from the urine - - - - - - - - But there ls nothing to prevent fomentations arrl cerates being
applied for the other pains of the sides; and
the legs and loins may be rubbed with hot oil,
or annointed with fat; linseed too, in the form
of a cataplasm, may be applied to the hypochondrium and as far np as the breasts. When pneumonia is at its height, the case is beyond remedy
if he be not purged, and it is bad if he has
dyspnea, and the urine is thin and acid, and if
sweat comes out about the head and neck, for such
sweats are bad, as proceeding from the suffocation, rales, and the violence of the disease
which is obtaining the upper hand, unless there
be a copious evacuation of thick urine arrl the
spute be concocted; when either of these come
on spontaneously, that will carry off the disease. A linctus for pneumonia: Galbanum and
pine-fruit in attic honey, and southern wood in
oxymel; make a decoction of pepper and black

-3-

hellebora, and give it in cases of pleurisy
attended wit~ violent pains at the commencement • "
The above quotation gives one a very good idea of what
general therapy was in the embryonic stage of medicine.
Wells (5) recorded that during the early
Christian era, Aretaeus described pneumonia as being
characterized by high fever and oppression of the chest.
From his complete description, one can recognize a
pretty good picture of pneumonia.

He was the first to

call attention to the fact that the sputum might be
tinged with bright red blood.

During this period,

Thenison treated pneumonia by me.ans of baths and inunctions of oil -- measures which continued to be used up
to the middle of the nineteenth century (5).
Neuburger (7) in describing the specialized
k nowledge of the treatment of pneumonia found in "Corpus
Hippocraticum 11 , noted that according to "De locis in
hominen the treatment consisted in warm lotions, poultices, inunctions with oil, warm baths and diet; while in
0

De victu in acutis", the use of infusions and their

correct dosage is stressed.

Active measures were not un-

dertaken before the seventh day; amongst these were
sternutatories and expectorants in order to get rid of
the mucus and injection of fluid into the windpipe in
order to provoke cough.

-4-

Galen (130-201 A.D.), as shown by Neuburger (7),
distinguished pneumonia from pleurisy much more sharply
than his predecessors and noted as differential diagnostic signs, the greater dyspnea and bloody sputum of the
former.

For the treatment of· pneumonia and pleurisy

Galen wrote:

11

in addition to poultices the most import-

ant part is played by blood letting and purgatio,n. 11 •
Howard (3) observed that in the writings of the
Arabians, Rhazes and Avicenna, who lived in the ninth
and tenth centuries respectively, one can recognize
little or no further contributions to the knowledge of
pneumonia.

Evidently the position of pneumonia in medi-

cal science remained in a status quo from the tenth to
the eighteenth century as no changes in treatment or
innovations of any significance are noted in the literature.
In 1761 Leopold Auenbrugger, according to
Major (5), published his book of ninety pages on

11

New

Invention, by means of percussing the human ches-c; as a
sign of detecting obscure diseases in the interior of
the chest".

This was the outgrowth of years of percuss-

ing wine kegs for his father to determine the fluid
level in the kegs.

The physical signs of pneumonia were

first recognized by Auenbrugger and he became known as

-5-

the father of percussion.
Howard (3) states that Laennec (1819), the father
of auscultation, Cruveilhier (1829) and Rokitansky (1842)
were the first to give a complete description of the
gross morbid anatomy of the disease.

It was Rokitansky

who apparently first differentiated between lobar and
lobular pneumonia.

Our present clinical knowledge of

pneumonia began largely with the excellant descriptions
of Laennec.

Heffron (4) writes that in 1819 and 1820

Laennec described the pathologic changes arrl physical
signs found during the course of the disease, advanced
methods for distinguishing between this and other diseases
of the chest and for the first time made clear the clinical different iation between pneumonia and pleur i sy.
Todd (8) in 1852 gave a good description of his
treatment of pneumonia which was instrumental in starting the supportive method of therapy and led the way to
the belief that disease means a weakened constitution.
He used flannels soaked in warm spirits of turpentine
and applied these to the back and side ov er the region
of dulness.

These stupes were applied three times.a

day for the first three or four days and were kept on
for half an hour.

I

At the same time a diaphoretic medi-

cine was administered, consisting chiefly of the liquor
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ammoniae citratis, of which as much as six drachms
were g iven every three or four hours.

An occasional dose

of a mild aperient medicine was g i ven and the patient
was allowed a pint of beef t.ea daily with a little milk
and ·bread.
used.

In addition

uo

t h is re g ime, leeches were

Todd stated that the treatment recommended by

some of the highest authorities during this period was
bleeding and tartar emetic.

Bleeding early from the

veins of the arm and if necessary b leeding a second or
'

· t h ird time was a common procedure.

If resolution did

not take place quickly, local bleeding by leeches or by
cupping was resorted to am tartar emetic was given more
or less freely.

At this time, it seems that Todd was

just beginning to revolt a gainst the common practice of
bleeding and the use of tartar emetic in the treatment
of pneumonia.

Nevertheless, the fact that he was in-

fluenced by the standard therapeutic measures then employed is evident by his continued use of leeches in
some cases along with what he thought to be a more
rational ap proach to the manag ement of this disease.
As the result of post-mortem examinations of 18
fatal cases, Stiles (9) in 1866 formed the opinion that
the treatment indicated by the patholog y of pneumonia was
one that would promote the absorption and elimina tion of
the exudate.

He felt that ammonium carbonate in drachm
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doses of a solution containing a drachm of carbonate to
a fluid ounce of water every two or three hours was of
definite value.

The general opinion at this time, as

upheld by Bennett and Flint, favored the use of
ammonium chloride which was bel ie ved to be ct: marked
therapeutic importance (9).
In 1881, Louis Pasteur and St ernberg isolated
the pneumococcus from saliva (3).

This was the result

of an increase in the number of investigations of
pneumonia under the impetus of the discovery of bacteria
and their possible relation to disease.

It was only

natural that with the acceptance of the germ theory of
pneumonia an active search was begun for solll3 antagonistic
drug which would act upon the organism in situ.
began the antiseptic treatment of pneumonia.

Thus

Calomel

treatment employing the inunction method and the injection of corrosive sublimate into the lungs was used
extensively on the basis that mercury possessed antiseptic
properties.

Schwartz in 1881, as recorded by Garlani (1)

used iodine and the iodide of potash, and obtained remarkable results.

He said:

11

I come therefore to the re-

sult that iodine or iodide of potash is a true specific
agent a gainst the pure uncomplicated croupous pneumonia;
that it will check the further development of the disease, if employed from 24 to 36 hours from the beginning
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of the chill.

It will abort pneumonia."

During this

period patients were not bled as frequently nor given
tartar emetic nor purged actively.

Stimulants,

opiates and nourishment were the main-stem of therapy (10).
Even in 1875, Juergensen (11) objected to the use of
tartar emetic, veratrine, and digitalis in pneumonia
and wrote that the antifebrile action of venesection was
slight and uncertain.

His strong sentiments against

bloodletting are clearly shown by his words.

"'The

physician who bleeds in pneumonia on account of the
fever, resembles the philosopher who cuts down the fruit
tree in order to get the fruit."

Later in his section

on treatment he wrote that venesection was clearly
indicated in passive pulmonary edema as it lessened the
force of the heart's action and permitted the absorption
of the pulmonary edema to take place.
In 1889 Smith (12} gives a good account of the
accepted form of therapy and the management of pneumonia
at that time.

It is noteworthy that he advocated plenty

of fresh air, an abundance of water for duiretic purposes and a limited liquid or soft diet.

During this

period many authorities showed a tendency toward
"therapeutic nihilism".

Osler (13) about this time

wrote that "pneumonia is a self-limited disease and runs
its course uninfluenced in any way by medicine.

-Id ...

It can

neither be aborted . nor cut s h ort , by any k nown means at
our command.
pneumonia."

We have no specific treatment for
Many physicians held w'i th Osler in claim-

ing that pneumonia is a self limited disease but there
are others who took exception to Osler's beliefs and
felt that there was a specific rem_e dy for all disease.
These men treated pneumonia with tincture veratrum
viride, 3 or 4 drops every 3 or 4 hours until the pulse
dropped to 70 or 80 beats per minute and the temperature
to 100 or 102° F.

A prescription used was: Quinine

selfate grains 30; powdered opium grains 2; fluid
extract of ipecac, drops 8:
capsules.

Sig:

Mix and make into ten

One every three h ours.

Hot water bags

on the feet and mustard plaster on the spine.

Calomel

and soda of each grains 1-2 followed by magnesium sulfate
three hours later.

Smith also took exception to

Osler's belief, maintaining that a rational treatment was
essential.

He felt that the foremost drug to be used

for its anti-microbic influence was mercury in the form
of calomel given e a rly in single doses of 30 to 50
grains.

Chloroform, also, was thought to have a power-

ful g ermicidal effect and by inhalation was "br ought into direct contact with the culture medium itself" (12).
According to Smith (12) Clemens, of Frankfort, employed
chloroform in his private practice since about 1850 and
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attributed the effectiveness of the anesthetic to the
sedative action upon the nervous system, lessened shock, and
easier respirat ion.

It was also his opinion that

chloroform defibrinated the blood in the lungs thereby
preventing hepatization.

Among othe'r measures, Smith

used quinine, creosote, solicylates, carbolic acid,
and nitrites, all of vvhich were thought to play some
specific part in combating the disease.

Potassium

iodide was given in 1 gram doses every 3 hours day and
night as a diuretic.

To promote perspiration, the wet

sheet was applied with a blanket over it and Dover's
powder administered.

As a cardiac stimulant, strychnine

in doses of grain 1/60 to 1/30 was used and tincture of
strophanthus was preferred to using digitalis.

Alcohol

was prescribed in all cases with an asthenic tendency
and even cases are cited of complete cures of apparently
hopeless patients by treatment with brandy alone.

For

the relief of pain, 1/4 to 1/3 grain of morphine was
I

used and in cases in which the use of morphine was
deemed inadv.isable an ice bag or in sthenic cases wetcupping or the application of a dozen leeches was recommended.

Blood-letting was still practiced oo casionally

although the use of the lancet by this date had passed
out of the therapeutist's armamentarium.

Oxygen lnnala-

tions were commonly resorted to in cases of severe dyspnea

-11-

and it was surprising to find that oxygen had been used
in this country since 1860 at which time Smith (12)
claims to have introduced it.
In 1897 a diplococcus ·known as the SternbergFraenkel diplococcus was found to be present in. about
75% of cases and was considered to be an important
factor in the ·production of croupous pneumonia (14). _
It "'!as during this period that Baruch (14) said: "A.ocording to my view cf pneumonia crouposa, the tmrapeutic indications are (1) to stimulate and invigorate
the nerve centers with a view to enhancing the patient's
vital powers, (2) to prevent and control heart failure,
(3) to reduce the temperature and (4) to eliminate
toxins. u

He be lie ved that pneumonia was an infectious

disease whose chief attack was upon the nervous syste~,
as manifested by heart failure, and other signs and that
treatment should be applied to the patient and not to the
disease.

He advocated calomel in large doses followed

by wet compresses, adapted induration and temperature

to each case, with fluid diet, an abundance of water
internally, mild alcoholic stimulation and hypodermics
of strychnine if needed and an occasional dose of
morphine for pain.
The definite periods in treatment cf pneumonia
are as distinct as styles and as easily recognized as one

-12-

peruses the literature.

It is cµ ite evident that the

profession gradually began to realize that the course
of pneumonia was but little influenced by medi cine and
that a careful regimen was important.

Up to 1910 there

had been a myriad of vaunted specifics brought to attention . through the medi cal press.

Flint once claimed

that quinine in 20 to 40 grain doses would abort
pneumonia.

Schwartz, as has been stated, claimed that

iodine was a specific, and at different times, veratrum
viride , carbonate of ammonia, ergot, salicylates, sodium
benzoate, creosote carbonate, calomel, and other drugs
claimed this distinction (2).

It was about 1910 that

vaccines and serums c ame into prominence and changed the
conception of pneumonia as well as its management .
As early as 1888, Netter, according to Smith (12),
rendered mice and rabbits immune to pneumonia by injecting t h em with fluid prepared from the dried spleen of
pneumococcus infected animals.

Later, he experimented

with an old pleuritic exudate containing pneumococci,
and finally with the avirulent sputum of a pneumonic
pa tient.

Heffron (4) writes that in 1886, Frankel

observed that rabbits recovered from an experimental
pneumococcus infection were resistant to a subsequent
inoculation with the same organism.
confirmed by other workers (4).

-13-

This finding was

The Klemperers, as re-

corded by Heffron (4) demonstrated that the young of
actively immunized motner rabbits usua lly acquired protection and also showed that normal rabbits could be
protected from fatal infection due to inoculation with
pneumococci by injecting into their blood stream the
serum of actively i mmunized rabbits.

In 1891, the

Klemperers as shown by Heffron (4) treated six pneumonia
patients with small subsutaneous doses
serum.

of immune rabbit

Evidently this was the first attempt made to

administer immune serum for the treatment of pneumonia.
It was thus established in the eighteen-nineties that
pneumococci injected parenterally into the anima l . body
acted as antigens in that they induced immunity a nd that
the serum of animals thus i mmunized possessed protective
bodies (4).

Howard (3) found that the antipneumococcic

sera of the Klemperers 1901, Raemer 1905, and Neufeld
and Haendel 1910, received clinical trials between the
years 1898 ar:rl 1914.

He writes that according to

Elsworth Smith 784 cases treated wi th one or another of
these sera showed a combined mortality of 17.3 per cent
as compared with a 20.45 per cent mortality in eash of
two series of 508 and 855 non-serum cases.

The poor re-

sults obtained with these earlier sera were due to the
fact that they were prepared without any regard to the
particular strain of the pneumococcus and it was not un-

-14-

til the recognition of pneumococcus types made accurate
bacteriolog ic diagnosis a possibil i ty that serum therapy
became a rational procedure.

As shown by Heffron (4)

Neufeld and Handel in 1909 and 1910 described means of
produ cing specific serums of high potency and emphasized
the importance of using,early in the disease, large
doses of serum intravenously.

Investigation of other

workers has led to modific a tions in serum therapy.

In

1918, Keyes, according to Howard (3), produced a polyvalent

antipneumococcus serum by injecting massive doses of

virulent pneumococci into the domestic fowl which is
resistent to the pneumococcus.

Human convalescent seru..~

has been used intermittently in the treatment of a
number of cases as also was Huntoon 1 s Antibody Solution
which is a concentration of the antibody of immune horse
serum developed by Gay and Chickering in 1915 (4).

More

recently, Barnes and White in 1934, according to Heffron
(4), found that serum of much higher specific antibody

content could be obtained from rabb its than from horses.
There have been subsequent investi gations by Bullowa and
others reporting favorable results in the treatment of a
number of cases of pneumococcus pneumonia with specific
immune rabbit serum (4).

-15-

General Mana~ement

In our present day enthusiasm for chemotherapy,
we must not forget the many symptomatic and supportive
measures which make the difference between treating the
patient with his dise·a se and treating the disease alone.
It is important that in every case of pneumonia we follow a general regimen of care designed to preserve
strength, insure comfort, maintain nutrition, and
alleviate distressing symptoms of the patient.
It is essential that bed rest with complete
physical and mental relaxation be carried out completely.
Active motion should be sharply curtailed throughout th~
febrile course.

The patient should be in a semi-sitting

position with trunk elevated about 30 to 45 degrees using sufficient · pillows for comfort of the patient.
This position usually allows the patient to breathe easier.

Since adequate nursing care is important, patients

who cannot have such care at home should be sent to a
hospital (15).

Cecil (16} states: "There is probably no

disease in which the services of a competent, well-trained
nurse are more valuable."
It is the opinion cf

Heffron (4} that orthopnea

is uncommon in pneumonia and therefore most patients are
more comfortable flat

in

bed.

-16-

Heffron advocates changing

the patients position about every two hours to avoid
the danger of hypostatic congestion and of massive
pulmonary collapse from retained pulmonary secretions.
The sick roo'm, as Finland ( 15) points out,
should be quiet and well aereated and the patient
should be kept warm and protected from drafts (16).
The exposure of patients to very cold air, as was the
practice widely used not very many years ago (11), has
proved to be ineffectual and the more moderate method
of supplying a continuous amount of cool but not cold
air has been substituted.
Oral hygiene is important.

Drying of the

mucous membrances of the mouth and throat as a result of
mouth breathing in dyspneic patients causes irritation
and makes respirations more difficult (4).

Saline er

boric acid solutions may be used to swab the mouth and
tongue and li.quid petrolatum or 'cold cream may be rubbed
ON er

the li:i:;s ( 4) ( 15) •
The diet ls of minor importance since the

disease runs a short course and therefore does not require a high caloric intake (4) (16).

Cecil (16) ad-

vises a liquid die ·t consisting of milk, cream, broth and
fruit juices.

Finland (15) advocates a soft diet, easily

digestible and supplying bulk and salt.

He supplies a

liberal amount of fruit juices to maintain sufficient

-17-

vitamin C intake and broths and soups to insure salt
intake.

Eggnogs with 20 per cent cream and added

lactose are given as a rich source of calories.

Warm

gruels, crackers, milk toast, and pureed vegetables
are provided to supply a certain amount of bulk to assist
peristalsis.

According to Heffron (4), Cole has ad-

ministered from 5 to 8 grams of sodium chloride daily
in addition to that in the diet and notes that it may
have been of aid in relieving distention and sy:¢ptoma
of toxemia.

Since chloride content as well as the

vitamin C level of the blood are usually low and
difficult to maintain in pneumonia (15), salt therapy
and fruit juices are definitely indicated.

As large

amounts of fluid and food are not well tolerated, small
and frequent feedings should be offered and the pltient
should be forced to take ample amounts of fluid (4) (15)
(16).

High fluid intake is important and most authorit-

ies (4) (15) (16) agree that patients should receive
2500 to 4000 cc. in the twenty four hour period.

Heffron

(4) believes that fluid in sol1'l3 form should be offered
every one or two hours.

The present day use of chemo-

therapeutic agents makes it even more important that
sufficient amounts cf fluids be taken by the patient s0
treated (17).

-18-

It has long been considered necessary to
I

give a purgative early in the disease and turpentine
stupes and enemata have been an "old standb y" for
distention (3) (4) (15) (16).

Bullowa, as described

by Heffron (4), considers the administration of cathartics
at the onset of disease unnecessary and frequently inadvisable because of the fluid loss associated with such
procedure.

During the course of the illness, if ·it is

necessary to ~ep the bowels open, Heffron (4) advises
the use of a daily saline or s_o apsuds enema.

If there

is any tendency towards the development of tympaintes,
Finland· (15) recommends a warm enema of 2 or 3 glasses
of soapy water or salt solution (one teaspoonful of salt
to the pint)given daily.

Heffron (4) states that "hot

fomentations apd turpentine stupes usually afford
sufficient relief" if drastic measures need to be used
for the distention.

Enemas of variou~ types have been

used in the treatment of distention.

Heffron (4)

feels that a soapsuds enema is the simplest and best.
However, according to Heffron (4), enemas consisting
of two ounces each of magnesium sulfate, glycerine, and
water; a mixture of equal parts of warm milk and molasses;
or the use of ox g;tle, magnesium sulfate, or castor oil
have all had their advocates.
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The use of pituitrin in

0.5 to 1.0 cc. doses given hypo d ermically has been used
with some success when other methods for the treatment
of distention have failed (4).
In severe infections symptomatic relief, as
Cecil (16) says, "becomes one of the physician's most
important duties".

Anything that will add to the

comfort of the patient and relieve pain enables hi m to
:i;reserve strength and better fight his disease.
Pleural pain is one of the most distressing symptoms in
pneumonia because it interferes with rest, sleep,
adequate respiration, and to a lesser degree with
cardiac functions (4) (15) (16).
is urgent.

Therefore, its relief

It is the consesus of opinion (4) (15) (16)

that a firmly fixed chest binder is the most satisfactory
method of controlling pleural pain.

Local heat in the

form of a hot water bottle or electric pad applied over
the painful area may be helpful (15).

Since pain is

the best indication for the use of morphine, it should
be used not only to relieve pain, but, as Cecil puts 1~
"to give the patient re st and sleep. u

Finland ( 15)

feels the dose of morphine should be adequate to relieve the pain and consequently he advises 1/8 to 1/4
grain hypodermically given, at the most, two or three.
times a day.

In patients showing an excess of moisture

in the lungs, morphine is contraindicated in the opinion

of Cecil (16).

Heffron (4) uses oxygen therapy with

morphine when the lungs are extensively involved or are
"wet".
Another troublesome sympton is cough.

If it

is harassing and unproductive, it increases fatigue and
interferes with sleep (4).

One quarter grain of codeine,

if necessary, may be given every four hours (4) _(15).
Although many physicians feel expectorants to be of
no value (4) (15)~

Finla nd (15) states that distress

and irrit a tion may be decreased by giving syrup of
hydriodic acid or elixir of terpene hydrate in one or
two teaspoonful doses.

Heffron (4) believes that

potassium or sodium iodide or ammonium chloride may
help raise the sputum with less difficulty.
Restlessness and insomnia in patients without
marked pain may be relieved by chloral hydrate, bromides,
or paraldehyde (4).

Cecil (16) advocates sodium

bromide, phenobarbital or some other barbiturate.
According to Heffron (4) Blake has reported that the
use of barbital and its dervivatives cause excitement
in patients with pneumonia.

Locke , as noted by Heffron

(4), states that hydrotherapy is the best sedative in
the presence of either deliraum or insomnia.

Some

patients may be quieted by applying an ice-bag to the
head (4).
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In our present day, digitalis is not used
routinely as it was in times past.

The studies of

Niles and Wyckoff (18) and of Cohn and Lewis (19)
have shown that the routine use of digitalis has no
apparent value and does not appear to influence the ou~
come in the general run of pneumonia cases.

The figures

presented by these groups suggest that the fatality rate
may be somewhat less in cases which are not given the
drug routinely.

Finland(l5) believes that digitalis

should only be given when there is evidence of congestive
heart failure or auricular fibrillation.

Heffron (4)

gives the dosage as two or three l½ grain pills, depending upon the patients weight, taken three times daily
for two days and then one pill a day as a maintenance
dose.
Although Smith (12) claims to have used ·
oxygen to treat dyspnea in pneumonia as early as 1860,
it was but little used before World War I (1914-1918).
Since then, t _he use of oxygen as a therapeutic measure
for the relief of dyspnea and cyanosis has become universal.

Heffron (4) observed that the clinical indi-

cations for oxygen therapy in pneumonia as advised by
Bullowa are ( 1) considerable increase in

t,

he depth of

breathing (2) respiratory rate of 36 per minute or over
(3) use of accessory muscles of respiration (4) pulse
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rate of 120 or more and (5) when cyanosis or dyspnea
is present.Bullowa would also ad.minister oxygen to
patients with distention.

Although it is best to give

oxygen to all patients with pneumonia showing increased
respiratory or pulse rate, in practice only those
patients with cyanosis or with marked respiratory
distress are favored with the administra tion of the gas
( 15) •

For the administration of oxygen a choice of
apparatus now available may be made between (1) nasal
catheter (2) the Bullowa inhalator (3) the BobthleyLovelace face mask (4) the face tent and (5) the oxygen
tent (20).

The first effective use of oxygen was

by nasal catheter.

This was later replaced by expensive

oxygen chambers and at tne present the oxygen mask or
tent has preference (21).
Since the advent of chemotherapy, the need
for oxygen in treating pneumonia patients .is not so ·
great.

However, in the opinion of Dimrnock (22),

oxygen is especially indicated in certain cardiaccases
and frequently adds much to the comfort and sense of
well being of the patient .

If the oxygen tent is not

available, the results obtained by giving oxygen through
the nasal tube are very satisfactory. (22)
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Roentgen 'rherapy
According to Settle (23} Mussar and Edsall
in 1905 first described the favorable influence of
x-rays int he treatment of unresolved pneumonia.
Q,uimby and Quimby ( 24) in 1916 reported the successful treatment of unresolved pneumonia with the use
of roentgen therapy.

Since that time there have ap-

peared in the literature scattered reports describing
varied successes in the x-ray therapy of unresolved and
acute pneumonias (23).
Although Cecil and Lawrence (2) are of the
opinion there is no rationale for the x-ray treatment
of pneumonia, recent investigations tend to s h ow that
roentgen therapy has a definite place in the modern
armamentarium for the treatment of lobar pneumonia.
In 1937, Fried {25) successfully treated by
roentgen therapy artifically produced pneumonia in
guinea-pigs which pathologically resembled lobar pneumonia.

He felt x-ray therapy was beneficial because

grossl y the lungs of the control animals showed complete hepatization, while the lungs of the irradiated
animals appeared almost normal vdth only scattered
areas of pneumonia.

Similarly, on microscopic examina-

tion, the irradiated lungs showed less congestion, edema,
infiltration, and abscess formation than the non-treated.
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Following this, Powell (26) in 1938, reported the use
of roentgen therapy in 104 cases of lobar pneumonia
collected over a period of four and one-half years.
These cases included infections vi th types I, II, and
III pneumococci as well as the higher types and other
bacteria.

Only 5 of the :p3.tients died giving a

mortality rate of about 5 per cent.

In 1939 Solis-

Cohen and Levine (27), following the technique of
Powell, produced favorable results in their series of
42 cases of lobar pneumonia.

Settle (23) in 1941 employ-

ed roentgen therapy to the exclusion of specific drugs
or sera in the treatment of 34 cases of lobar pneumonia.
He reported that this treatment produces a typical
clinical reaction characterized by relief from pain,
decreased temperature, marked improvement in the
patient's general condition, a decrease int re leucocyte
count, an:i resolution of the consolidation.

The thera-

peutic regimen consistently used by Settle consisted
of early x-ray therapy plus the usual supportive
measures and nursing care employed in the treatment of
pneumonia.

The technique used by Settle was similar

to that recommended by Powell (26).

Of the 34 cases

treated, 32 were report·e d as recovered and 2 patients
died giving a mortality rate of 6.2 per cent for this
form of therapy in this particular study. ·

_<;>!;_

A very well controlled investigation concerning the use of x-ray therapy in pneumonia has been reported in March, 1942, by Rousseau, Johnson, and Harrell

(28).

Their observations were made on two series of

acute lobar pneumonia patients treated since 1937.
Roentgen therapy alone was used in the first series.
However, the usual supportive and symptomatic measures
were employed.

In the second series, a through trial

of sulfonamide therapy, over a period ranging from
three to seven days, was given before x-ray treatment
was used.

Clinical diagnosis .of pneumonia was confirmed

in all cases by demonstration of the pneumococcus in
the sputum and an x-ray film of the lungs.
series 104 cases were treated.
recovered and 6 died.
was 5.7 per cent.

In the first

Of these, 98 patients

The mortality rate in t h is series

It was noted that a fall in

temperature, pulse, and respiratory rate usually occurred
in 12 to 36 p.0 1.l.I's after the first treatment.

The

temperature fell by rapid lysis int he majority of
cases, reaching normal within 24-48 hours after the
initial decline.

Clinical improvement was well developed

before any change could be demonstrated by x-ray and the
convalescent time in this series was reduced to about
half that usually observed in pneumonia.

In the second

group of patients, it was evident that the course of the
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disease had not been favorably affected in any way by
sulfonamide therapy as the patients were becoming
progressively worse with adequate doses of the drug.
In this group only 29 cases were collected.
22 reco~ered and 7 died.

Of these

The mortality rate in this

second series thus being 27.1 per cent.

The response

to roentgen treatment in this series was the same as that
previously noted in cases in which the sulfonamides
had not been used.

Although this second series is

small, it may be justly assumed that x-ray therapy is
of definite value in pneumonia patients who fail to
show a satisfactory response to chemotherapy (83).
In the opinion of these authors, roentgen treatment in
pneumonia appears to have distinct advantages (1) among
patients who do not tolerate sulfa drugs well, (2)
among the very old and debilitated, and (3) those with
serious heart, kidne y, or liver disease, in whom the
toxic effects of the drug would be overwhelming.
From the evidence presented, it is obvious
that roentgen therapy is beneficial in pneumonia,
decidedly retarding the progress of the disease.
The ready accessibility, low cost, ease of administration, and minimal, if any, ill effects make this form
cf:

treatment preferable to the use of serum as a sub-

stitute for the sulfa drugs.

- •.,..1 r;_

Further work and clinical

trials are needed to support the reports already
present in the literature.

It will be interesting to

f ollow and observe the fate of this type of therapy.
At the present time we should regard the roentgen ray
as a potential ally ever present and ready to assist
those cases of pneumonia vvhich cannot be benefited by
simple use of the sulfonamides.
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Serum TheraEI

Since serum is

still used and considered bene ficial

in some cases of pneumonia, its use must necessarily
be discussed here.

The routine method of administra-

tion, dosages used, and the precautions necessary to
observe in giving serum can be found in any textbook
of medicine and, therefore, shall not be included in
this paper .
cf

At the present time, it is the consensus

opinion (29), (30), (31), (32), that serum treatment

should be substituted for chemotherapy if there is no
response to the drug after 36 to 48 hours, or if serious
toxic symptoms appear provided there is a specific
pneumococcus organism present .

Finland (29) also

considers serum, in addition to sulfonamides, to be
helpful when there is a very severe bacteremia.
Recently, 36 serologically distinct types of
pneumococci have been identified (33).

Horse anti-

serums for types 1, 2, 4, 5 , 7 and 8 are commercially
available as monovalent or bivalent sera.
states that types I and II , V and VII , and

Finland (15)
IV and VIII

are 3 common pairs of types used in the bivalent sera,
but others can be obtained.

As Lord, Robinson and

Heffron (34) believe there is no reason for preference,
either the monovalent or the bivalent serum may be used .
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Rabbit antipneumococcus sera have been introduced only
recently.

They are obtainable for all the recognized

types of pneumoccus pneumonia (34).

Rabbit antiserums

are all monovalent (15) and usually contain more
units per cubic centimeter than the corresponding horse
serums.

Therefore, the volume of a given dose for

clinical use is less with concentrated rabbit than
with the concentrated horse antiserum.

Since the

success of serum therapy depends on introducing large
amouhts of antibody in a short time, it is obvious
that the more concentrated rabbit antiserums are
desirable.

In the treatment of patients who have had

previous horse serum inj e c tions or are sensitive to
horse serum, rabbit sera are naturally preferable (15).
The administration of antiserum to a pneumonia
patient produces a marked improvement in the clinical
picture within eight to twenty-four hours.

A more

favorable response is noted when patients are treated
early (34).

The patient becomes clearer mentally and

begins to take an interest in his surroundings (35)
(36).

Concomitant with this improvement there is

generally a marked alleviation of the acute symptoms.
Otanosis, dyspnea, chest pain of the more severe type,
delerium, and toxemia are largely or wholly relieved
(37) (38) (39).

In most cases the temperature drops
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three or more degrees and does not again reach its
former level (35} (36).

At the same time, though less

rapidly, there is a fall in the rate of the pulse and
respiration.

Sutliff and Finlan:l (38) found that in

patients not treated with serum, a much smaller
proportion show symptomatic improvement and a sharp
drop in temperature during the course of the disease .
Low grade fever and lesser complaints may continue
for several days following the initial fall in temperature of serum treated cases .

Although x - ray

examination shows little change in the size and
density of the consolidated area, the progress of the
disease is ordinarily stopped (36) .
The value of serum therapy can best be ascertained
from its effect on the case fatality rate.

From a

large series of cases collected from the literature
by Heffron (4) it may be estimated that the case
fatality rate for Type I infections without specific
therapy is about 30 per cent.

Of 2,314 type I cases

occurring in the United States and Canada between the
years of 1912 an:l 1936, 671 or 29 per cent died .

In

contrast to these results of untreated cases, Heffron
(4) finds that of 4,448 type I serum treated American
and Canadian cases reported in the literature, only
732 or 16.5 per cent died.

Comparison of these
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fatality rates indicates a reduction in the rate for
the treated cases of 43 .1 per cent.

Ev:id ence was

presented to show that specific serum treatment is
also effective in cases due to types 2 , 5, 7, 8 and
14.

Results tabulated by Finland (40) in 1937 showed

that the prompt use of type specific concentrated
antipneumococcus horse serum cut the mortality rate
in half in all cases of pneumonia of types 1 , 2, 5
and 7.

Equally striking results were obtained when

only bacteremic cases were considered.

Comparable

results were obtained in all types with homologous
antiserum except in cases of type III pneumonia .
More recently the use of rabbit antipneumococcus
serum has evidenced more favorable results than those
obtained wi th horse serum .

Horsfall, Jr. ( 41) and his

associates in 1 937 presented the first clinical report
on the use of antipneumo coccus rab b it

serum.

Their

re po rt concerned 22 cases, 10 of type I with no deaths ,
4 of type II w ith one death, 3 of type VII and 5 of
type VIII with no deaths .

The only death occurred

five weeks after the onset of the disease from
rupture of an aortic aneury§ m.

Later reports of

Horsfall ( 42) included clinical experience with 67
patients suffering from nine different types of
pneumonia .

lobar

Thirteen of the cases were due to type III
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pneumococcus .

No evidenc e that rabbit antiserum was

beneficial to these cases was obtained .

In the re -

maining 54 cases composed of eight different types
of pneumococcus pneumonia , the mortality rate was 3 . 7
per cent .

Lord, Robinson and Heffron ( 34) obtained

from the literature a combined series of 867 adult
cases of pneumonia caused b) pneumococci of various
types .

These cases , treated with specific rabbit

antiserum at various stages cl'

the disease , resulted

in 80 deaths or 8 . 3 per cent mortality .

It is interest-

ing to note that in 49 collected cases of type III
pneumonia treated with rabbit antiserum there were 15
deaths or 30 . 6 per cent mortality as compared with the
expected rate of 46 per cent.

These figures suggest

some benefit in spite of the general impression of
the ineffectiveness of specific treatment·with this type
of infection

(34) .

Finland , Spring, and Lowell (43) in 1940 reported
the results of specific treatment in 1037 cases of
pneumococcic pneumonia admitted to the Boston City
Hospital during the year 1938- 1939 .

They concluded

that both horse and rabbit ser1.uns were effective in
reducing the death rate and in bringing about rapid
clinical improvement .

Rabbit serums were found to give

fewer allergic reactions than horse serums .
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As the

rabbit serums were more concentrated, they were used
in the poorer risks.
Although serum therapy has been widely accepted
and its value proven at the bedside, Finland (15)
notes that there are certain limitations in its use
which are well recognized:

(1) It is strictly type

specific in its action : hence failures may arise from
( a) technical errors in type diagnosis; (b) the
presence of multiple types in the sputum; (c) mixed
infections or super-infections with organisms

other than

pneumococci; or (d) failure to recognize the true
etiological agent when the pneumococcus found is
only an incidental contaminant. . ( 2) Cases of pneumococcus type III pneumonias , which constitute from 10
to 20 per cent of the total cases and usually are
associated with a high mortality rate, do not respond
regularly with s~ cific serum treatment alone .

( 3)

Serum therapy is expensive and is not justifiable if
the sulfonamides can effect a cure.
Kepl and Gunn (4) have shown that the combined
use of sulfapyridine and specific antipneu.~ococci~
serum in animal experiments is more effective than the
administration of either preparation alone .

The

investigations of Powell and Jamieson (45) support
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these findings.

It is to be expected then that the

combined use of sulfapyridine and antiserum in pneumococcus pneumonia will prove more effective than either
therapeutic agent alone.

The following clinical re-

sults tend to substantiate this expectation .

Lord,

Robinson and Heffron (34) collected from the literature
a series of 141 cases treated with both sulfapyridine
and specific serum.

There we r e 22 deaths or 15.6

per cent mortality re p orted in this combined series.
In 1939, Finland , Spring, Lowell and Brown (46)
reported their series of 80 cases.

All patients were

over the age of forty and 50 per cent showed a
bacteremia.

They reported 21 deaths or a mortality

rate of 26.3 per cent.

In similar cases without

specific serum or chemotherapy the expected fatality
rate is ·75 to 90 per cent and if serum alone is used
the mortality rate is about 50 or 60 per cent (34).
Stahle (32) in 1942 evaluated the effectiveness
of various therapeutic a g ents after analyzing 15,000
cases of pneumonia collected from the literature.

The

vast majority of patients w_ere treated with sulfapyridine or sulfathiazole either alone or combined
with serum.

The case fatality rate in this series was

9 .19 per cent.

This author's results did not substantiate
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the experimental stud ies in animals and in vitro
reporting the efficacy of combined serum and chemotherapy.

The g enerally accepted indications for

serum therapy in addition to the drug were not confirmed .

He concluded that the use of combined V1. erapy

depended upon clinical judgment / and should probably be
used for those patients who are extremely ill.
Frisch and Price (47)

in 1941 reported their four

year study of Wright stained smears of rusty sputum
obtained from patients with pn~umococcic pneumonia .
They noted that the number of extracellular encapsulated pneumoc occi in rusty or bloody sputum constituted
a reliable index of' the severity of the pneumonic
process and we re thus able to give an accurate
estimate of the prognosis in each case.

Twenty-four

of their patients had sputum counts exceeding 50 per
oil immersion field which was considered indicative
of overwhelming infection.

Most of these patients

showed bacteremia and t vi.o or more lobes involved
during the course of their illness.

These patients

were treated with large doses of serum in addition
to chemotherapy.

The mortality rate in this group

was 58 per cent in spite of the intensive therapy.
The inve stiga ti ons of Bull ow a ( 48) m d his col-
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leagues in 1940 led to the conclusion that. serum plus
sulfapyridine was a more effective therapeutic a g ent than either a g ent acting alone .
conducted

11

Their experiment was

in vitro 11 -using the technique of vaccine

vial culture of human marrow .
It is evident that the results reported concerning the efficacy of combined serum and drug therapy
are not cqnslstent .

However, in view of the fact

that favorable results have been obtained with
combined therapy, the serum plus the sulfonamide drug
should be used in all patients who are very 111.

It

has been recommendeµ by t h ose advocating comb~ned
therapy that the following cases of pneumonia receive
combined serum and drug therapy : (1) women who are
pregnant or in fir st week of pu·erperium , ( 2) pa tlents
with bacteremia, (3) patients with multiple lobe
involvement, (4) patients of fifty years or over (5)
when sulfoQamides alone fail to produce clinical improvement after 24 to 36 hours {34).
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C H E MO T H E R A P Y
------------

Cinchona Derivatives

Quinine has been in use in one form or anothe r
in the treatment of pneumonia for over 50 years.

It

was first used as a tonic, later as an antipyretic arrl
finally as a specific remedy (7), (11), {12), (13).
According to White (49), Morgenroth and Levy in 1911
investigated the properties of quinine and found it
to be valueless in overcoming pneumococcus infections
in mice .

In that same year, according to Heffron,

(4), Morgenroth and Levy reported the discovery of
ethylhydrocupreine (optochin), a quinine derivative.
This drug was reported to have a strong bactericidal
action on pneumococci in test tube preparations and
in experimentall y infected mice .

Recovery· of the mice

was noted in a high proportion of cases.

Moo re and

Chesney (50) in 1917 gave optochin a thorough clinical
trial in 32 cases in the hospital of the Rockefellar
Institute without lowering the mortality .

They employed

the drug in an initial dose of 7 g rains followed by
2 .5 grains every two hours until 1.5 g rams had been
given in 24 hours .

This was continued until clinical

improvement cc curred or until symptoms of toxicity
appeared .

These workers also collected from the litera-

-38-

ture 787 cases treated with optochln .

They found

that 36 or 4 . 5 per cent of these cases had either
amaurosis or amblyopia and in one case at least
permanent and almost total blindness resulted .

In

a later paper , Moore ani Chesney (51) pointed out that
the therapeutic effect derived from optochin is
negligible .

They strongly recommended discontinu-

ance of its use in the treatment of pneumonia .

The

more recent experiments of Reimann ~nd Moen (52)
support this view .
In 1937 Mac Lachlan (53) reported that the
addition of the hydroxy radical to ethylapocupreine
made this drug less toxic without interfering with its
ba ctericidal properties .

In another re p ort (54) , he

presents evidence of the clinical effectiveness of
this drug .

He used hydroxyethylapocupreine in a dose

of 1 g ram every three hours .

The mortality rate for

300 treated cases was approximately 30 per cent as compared with 50 per cent in 180 untreated cases .

Accord -

ing to Howard (3), Ma cLachlan in 1942, at a me eting
of the Association of American Physicians, reported
results comparable to cases treated by him with
• sulfonamides .

At the present time, however, there

have not been sufficient investi gat ions conducted with
hydroxyethylapocupreine to warrant lts use in the treatment of pneumonia .
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Sulfonamides

History

The sul!'onamides are undoubtedly the g reates t
single advance that has been made in the treatment
of pneumonia .

Since sulfanilamide first became

available to the medical profession in 1936, there has
literally been a torrent of literature reported
concerning sulfanilamide and its related compounds .
This g roup ct: drugs has already played a great role
in combating bacterial infection and in all probabli ty
are destined to play an even g re a ter part in the
medical profession ' s ceaseless fi ght a g ainst disease .
The history of the development of the sulfonamides
is indeed interesting and dramatic .

In a few short

years these drugs have been developed , accepted, and
app lied in the treatment of countless of patients
suffering with a variety of diseases .

The first

synthesis of sulfanila:.1ide by Gelmo in 1908 v:as the
result of his work with azo dyes in the German dye
industry (55) (56)
known as

(57) (58).

Th is substance, then

p - a.minobenzene -- sulfonamide was used only

in the dye industry until 1935 at which time Domagk
reported the antibacterial activity of the related
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compound known as sulfanido--chrysoidine or prontosil
(55) (56) (57).

About this time, the French investi-

gat ors Levaditi and Vaisman, using prontosil symthesized
in France by Girard, confirmed the experiments cf
Domagk (56) (56).

This compound was known as

rubiazol in French literature (56).

It is interest-

ing to note that the first clinical report upon the
use of prontosil described its effect upon a case of
wide-spread staphylococcal infection (55).
In 1936, Colebrook and Kenny (59) reported that,
using a French preparation , they had been able to
confirm Domagk 1 s original observation upon the efficacy of sulfonamido--chrysoidine as a curative agent
in experimental streptoeoccal infections in mice .
They also showed that this drug was of definite value
in the treatment of puerperal sepsis.

Their series

of 38 cases of peurperal sepsis received definite
beneficial effects from the use of prontosil.

About

the saroo time Buttle, Gray, and Stephenson (60) announced
that they were able to confirm the findings of the French
wo rkers regarding the antistreptococcic activity of
sulfanilamide in experimental streptococcal infections
in mice.
Up to this time American worker s had not taken
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much interest in the new chemotherapeutic compounds.
In 1935 and 1936 the spark was kindled and experimental
and clinical studies of the sulfonam ide drugs were
started.

In November 1936 Long and Bliss (57) reported

upon their experimental and clinical observations of
prontosil , prontosil - S, and para - aminobenzene-sulfonamide .
They confir me d the observation of Colebrook and Kenny
who noted the lack of bactericidal effect of prontosilS in vitro.

They also noted a definite bacteriostatic

effec,t when para-aminobenzene- sulfonamide was added
to

broth cultures of streptococci and certain other

micro organisms.

The hypothesis was advanced b y them

that this drug acted directly on the micro organism
thereby producing bacteriostasis.

It was soon after

this report that Rosenthal , as recorded b y Long and
Bliss (57), reported the therapeutic act i vity of
sulfanilamide against pneumococcus types I, II, and
III infections . in mice.

This work was soon confirmed

by Gross and Cooper (60) (61).

One of the earliest

reports of the clinical use of sulfanilamide in the
treatment of pneumonia was presented by Heintzelman ,
Hadley, and Mellon (62).

They described their results

with the drug in 9 cases of type III pneumonia and
reported a recovery in 7 of 9 patients as compared with
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recovery in 2 of 10 untreated controls.
With the widespread use of this drug, frequent
toxic manifestations appeared and there were many
patients who were found to be intolerant to the drug.
As a result

of

this, and due to the limitations of

sulfanilamide that were observed clinically, further
efforts were extended to synthesize derivatives of
sulfanilamide.

In May 1938, Whitby (63) reported

that sulfapyridine was therapeutically more active
than sulfanilamide in the control of experimental
pneumococcal infections in mice .

This was later

proved to be true in the treatment of the dirsease
in man.

Since the original re port of Whitby , much

confirmatory evidence has accumulated as to the value
of sulfapyridine in pneumococcal infections (64) (65)
(66) (67) (68) (69) (70).

Sulfathiazole is another

compound ½hi ch has been accepted for general use.
Fosbinder and Walter (71) and Lot t and Bergeim (72)
in 1939 announced the synthesis of this _compound.
Sulfadiazene was the next and most recent compound to
be accepted.

The synthesis of this drug was announced

by Roblin and his associates (73) in 1940.

They foun:i

that sulfadiazene appeared to be more active against
experimental pneumococcal infections in mice than
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sulfanilamide , sulfapyridine, or sulfathiazole .
recently a new drug bas been synthesized .
as sulfapyrazine (2 - sulfanilamidopyrazine ).

More

It is known
It bas

already been used clinically in the treatment of
pneumococcic pneumonia and favorable results were
reported (30) (74) .

Mechanism of Action

At the present time the exact mode of action of
the sulfonamide compounds upon susceptible bacteria
is a matter of conjecture .

Much experimentation

indicates that these compounds are bacteriostatic
in nature and interfere with the metabolism of
micro organisms by upsetting certain enzyme systems
which are essential for bacterial growth .

In vivo

and in vitro experiments have shown that bacterial
growth is inhibited by sulfanilamide and its related
compounds (57) .
There is a definite relationship between the
chemical structure and chemotherapeutic activity of-tlhe
sulfonamide compounds .

According to Goodman (75) , it

was determined early in the .course of chemical investigations of the prontosils, that the azo linkage ( - N9 N-)
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was broken down in the luman body to form sulfanilamide .
Following this, it was found that the therapeutic activity of sulfanilamide was related to the sulfonamide
group (-S02NH2) attached to the benzene ring. The
structural formula of sulfanilamide contains the
basic group which characterizes the sulfonamides in
ge neral.

This group H 2

N
·c=> S

o2

the free amino g roup in the para position .

N:

has

Goodman

states the potency of the drug is lost when the amino
g roup is placed in the me ta or ortho position or replaced by another group .

As noted by Spink (56), a

portion of these compounds taken into the body are
acetylated, i.e., conjugated by substitution of an
acetyl g roup for one of the hydrogens in the free
amino group .

This process of conjugat ion is thought

to occur, to a large extent, ' in the liver.

Marshall

and his associates (76) found that after a single oral
dose of sulfanilamide 10 to 20 per cent of the total
circulating drug was present in the blood in the conjuga ted form .

This acetyl deriva tive of sulfonam ide

is therapeutically inactive.
The problem of the mechanism of the anti-bacterial
action of sulf'anilamide has been well summarized by
Long and Bliss (57) as follows :

" * * * i t seems pos -

sibble to conclude that sulfanilamide does not arouse
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a specific response on the part of the host .

The

production of antibodies is not stimulated , and there
is no direct action upon the phagocytic mechanism .
On the other hand , there is considerable evidence that
the drug does act upon the micro organism in vitro
and in vivo .

Most workers are of the opinion that this

action takes the form of an inhibition 01· the g rowth
of the bacteria which brings about a suppression of
their invasive power, and which thereby per.n its the
defense mechanism of the host to accomplish its
function . n

Long and Bliss reached these conclusions

on the basis of their original investigations and arter
an extensive review of the literature .

Although mos t

of the investi gat ions to date ha ve been carried out
with sulfanilamide, it is quite likely that the same
mechanism of action holds true for the other sulfonamide
compounds .
Stamp (77) in 1939 discovered that the extraction
of hemolytic streptococci with dilute alkali yielded
a precipitate wh ich was able to neutralize the
bacteriost ati c f:?ffect of the sulfonamide drugs .

Woods

(78) in the following year found th&t yeast extract
cont ained a substance with properties similar to the
extracts of streptococci.

His
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studies suggested that

the active- factor was a substance probably similar
in chemical structure to sulfanilamide .

He found that

both substances possessed the same chemical and physical
properties as p a ra- amino - benzoic acid wh ich also proved
to exert antisulfonamide effects .

Woods suggested

that these substances are probably identical.

He

assumed that para- amino-b enzoic acid is essential ror
the growth of the organism and suggested that, because
of the similarity in t heir chemical structures,
sulfanilamide (para-aminobenzene-sulfonamide) interfered with the enzyme reaction necessary for the
utllization of para- a minobenzoic acid by the cell.
The investi g ations of Rose and Rox (79) indicate
that the antagonism between para-amino -b enzoic acid and
the sulfonamides is independent of the number of
bacteria, but is related principally to the critical
concentration of these compounds.

The occurrence of

an anti-bacteriostatic a g ent has also been reported in
extracts of certain animal organs , in pus , and in
sorre

sterile serous effusions found in certain diseases

(80).
The development of resistance to the sulfonamide
drugs by various strains of bacteria has been reported
in the literature by a number of investigators (81)
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(82) (32) (84)

(85).

This phenomenon seems to follow

the same course as is found in resistance to other
antibacterial substances and fu

quite similur to the

development of arsenical resistance in the trypanosomes
af African patients (85) .

This drug resistence has

been produced experimentally both in vivo and in
vitro by repeatedly passaging or subculturing a
susceptible organism in the presence of increasing
concentrations of a sulfonamide .

Schmidt and his

associates (85) found that once maximal resisteree of
a strain of some organism was wel l established, the
resistance could be maintained for long periods.

Some

authors believe that it is probable that this phenomenon
is in some way related to p-amino-benzoic acid (83)
(84).

It has alro been shown (86) (87) that pneumo-

cocci which become resistent to one sulfonamide are
also resistant to the other sulfonamide drugs.
Lockwood and his co-workers (88) (89) (90) have
advanced the theory that the action of the sulfonamides
is to inactivate a proteolytic enzyme present in
virulent organisms which is necessary for their growth
when their environment is free of protein-split products .
They are of the opinion that the presence of these
proteolytic products limit the bacteriostatic power of
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the drug and hence its effectiveness.

Thee ffects

produced by either of these substances is dependent
upon their concentration in the medium and, therefore,
bacterial growth would be proportional to their
relative concentrations.

Lockwood explains this

neutralizing action of peptone on the assumption that
sulfanilamide acts by interfering vnth the nutritional requirements of susceptible bacteria .

He fur-

ther assumes that the addition of peptone to the medium
supplies an excess of protein material which nulli fies the bacteriostatic eff~ct of the drug.

However ,

Osgood (91) has been able to obtain complete sterility
in marrow cultures containing 25 mg •. per 100 cc. of
neo-peptone.
After reviewing the many theories concerning the
mech~nism of the action of the sulfonamides, Osgood
(91) gives his opinion as follows:

"At present it

seems to me probable that these drugs act directly
on the organisms, producing definite changes in
morphology and ultimate death; that this process
requires considerable time; and that the most probable
explanation for the ineffectiveness against large
numbers of organisms is that the organis1lli3 tend to
produce something, possibly para-amino-benzoic acid,
as suggested by \\oods , which inactivates the d rug. 11
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Therapeutic Use
and Clinical Results .
The iiterature reveals that sulfadiazene, at the
present time, is the drug of choice in the treatment
of pneumonia .

Sulfathiazole is next in preference and

sulfapyridine is third in order of choice .

Sulfa-

thiazole and sulfapyr idine, as will be shown, are very
effective in treating pneumonia but sulfadiazene, as
reported by a number of investigators (17) (21) (92),
is just as effective but less toxic and is thus to be
preferred .

Sulfanilamide

The results of sulfanilamide in the treatment of
pneumonia have not been very encouraging .

The drug

has proved to be only mildly effective in this disease .
Finland (31) in a series of 1037 patients treated at
the Boston City Hospital found the drug to be somewhat disappointing in its results .

Faller and his

associates (93) in a statistical study of 3491 cases
cases of lobar pneumonia found that the average
mortality rate of cases treated with sulfanilamide
alone was found to be 15.6 per cent, compared with a
gross mortality rate for the entire series of 2~26 per
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cent, and a rate of 10.69 per cent for those patients
treated with sulfapyridin~ alone.

The report of Price

and Myers (94) sh owed a mortality rate of 15.7 per
cent in a series of cases treated by them with sulfanilamide alone .

As soon as the newer drugs, sulfa-

uyridine, sulfath iazole, and sul f adiazene proved their
therapeutic efficiency in pneumococ cus pneumonia,
sulfanilamide was abandoned as a chemotherapeutic
a g ent in p neumonia .

However, Long and Bliss (57}

have pointed out that therapy with sulfanilamide is
beneficial in the tre a tment of hemolytic streptococcal
pneumonia .
Marshall, Emerson, and Cutting (95} reported a
method of analysis of blood and ur·ine, as well as
certain other body fluids, for determination of
sulfanilamide in free and combined form .

Experiments

on do g s and analysis of blood and urine made after
administering sulfanilamide by mouth, subcutaneously
or intravenously indicated that this substance is
apparently absorbed and excreted rap idly .

In most

instances the drug could be completely accounted for
by direct determination on the urine .

No evidence

of its being changed in passing through the dog ' s
organs had been obtained .

The unchanged material was

isolated from the urine and i:i entified.
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It was found

that subcutaneous administration did not lead to a
higher blood concentration than oral administration .
A co mpa rison of the blood concentration and urinary
excretion after oral administration with those
resulting after intravenous injection sugg ested nearly
complete absorption from the intestinal tract within
three to five hours .

The rap idity of absorption was

checked by actual determination of the a.mount of drug
remaihing in the intestinal tract some hours after oral
admini strati on.
The human subject excretes sulfanilamide partly
unchan ged and partly in conjugated form and the
acetyl form may be excreted in breast milk in a
concentration varying from 35 to 93 per cent of the
total sulfanilamide con tent ( 76) •

In c ertain pat lent s

underg oing prolonged treatment with sulfanilamide
administered in divided

doses throughout the day,

Marshall and his co-workers ( 95 ) followed the urinary
excretion an::l blood level for several days.

It V!as

found that it takes from two to three days toe stablish
equilibrium between the amount ingested and the amount
excreted.

After equilibrium is established it takes

about the same time to free the organism of the drug.
lnlhe n the body is in equilibrium with respect to the
drug, one can frequently account for almost 100 per cent
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of the daily dose by the daily excretion in 1'ree and
conjugated form .

Blood concentrations were maintained

fairly constant for a long time .
In the

average case ,

in which sulfanilamide is

indicated, Schnitkrer (96) states that a blood level
of 7 -10 mgm . per cent is adequate .

Larger doses

are advised for critically ill patients .

It is thought

necessary to establish a blood sulfanilamide level
of 10 to 15 mgrg.. per cent for the more seriously ill
patients.

The oral route of administration is

sidered to be the best .

con-

The drug is given in an

initial dose of 15 grains per 20 pounds body weight
not to exceed a dose of 120 grains .
initial dose,
next 24 hours .

~ollowing the

a similar total dose is given during the
This total dose is divided into six

equal doses and 6 iven every four hours .
Toxic effects following the administration of
sulfanilamide have been reported by a number of works rs.
These reactions seem to be unpredicable in their oc currence and frequently suggest an idiosyncrasy to
the drug .

It is, therefore, advisable that the

patient be under daily observation of the physician
while being treated with this drug.

Long and his

colleagues (97) reported the incidence of the various
toxic manifestations noted in a group of 1,000 µ3.tients
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treated at the Johns Hopkin~ Hospital .

They found

that cyanosis was a very common occurrence .

Nausea

an:i vomiting was stated to be fairly common and
dizziness was only common in occurrence .

Fever was

noted in 10 per cent , rash in 1 . 9 per cent, acidosis
in 1 . 9 per cent (althoug h this was rare if sodiwn
bicarbonate was used), hepatitis in 0 . 6 per c ent ,
psychosis in 0 . 6 per cent, leukope~ia with granulocytopenia in 0 . 3 per cent , acute agranulocytosis in
0 . 1 per cent, mild hemolytic anemia in 3.0 per cent
and acute hemolytic anemia in 1 . 8 per cent .

Ocular

and auditory disturbances , stomatitus and gastrointestinal bleeding were rare .

These workers pointed

out that patients who have already proved intolerant
of sulf'anilamide are likely to be even more intolerant
of it on subsequent attempts at administration .

It

was generally agreed that one unsuccessful attempt to
use the drug contraindicates its further administra tion .

Sulfatlridine

Sulfapyridine was the first drug to give satis factory results in the treatment of pneumoco c cic
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pneumonia of all types.

Since the original report

of Whitby (63) in 1938, much confirmatory evidence
has accumulated as to its value in pneumococci c
infections.

Evans and Gaisford in 1938 reported a

series of 100 cases of pneumonia trea~ed by the drug
alone with a mortality rate of 8 per cent as compared
with a 27 per cent mortality rate in as many controls.
The following year Gaisford (99) reported 700 cases
of respiratory infection tre ated with sulfapyridine.
These included 400 cases of lobar pneumonia in which
the mortality rate a g ain was 8 per cent as compared
with the control mortality rate of 27 per cent.

A

similar reduction in mortality was reported by Long
and Wood (100), who observed a mortality rate of 7.2
per cent in 139 adult cases of pneumococcal pneumonia.
Smith and Needles (67) reported a mortality rate of
8.5 per cent in .his series and Pepper and his associates
(68) reported a death rate of 7 per cent in their
series of 400 cases.
Sulfapyridine differs from sulfanilamide in that
one hydrogen atom of the amide g roup in sulfanilamide
is replaced by the basic pyridine ring .

The structural
0 H

formula as given by Goodman (75) is H

2

-54-

N

C)g-No
ll

0

rt is a white , nearly tasteless , crystalline compound .
Sulfapyridine is absorbed rather promptly from the
gastro - intestinal tract, but not as rapidly or as
completely as sulfanilamide ( 34) (57 ) (65) (66)
(75) .

(67 )

Long ard Bliss (57) state that instead of

finding 85 to 95 per cent of the drug in the urine ,
as would be exp ected with sulfanilamide ,

the amount

of sulfapyridine exc reted into the urine after a
single dose varied from 39 to 79 per cent of the am ount
ingested .

The findings of these authors indicate the

drug usually reaches the spinal fluid in about · 60 to
80 per cent of its concentration in the blood and the
drug is generally present in pleurol exudates in a
slightly lower concentra tion than in the blood .

They

al so found that a Ja rger part of the drug in the blood

is acetylated than is the case with sulfanilamide .
Whitb y ( 10},) reported that sulfapyridine is ex_creted
in approximately equal proportions as the free and the
conjugated forms, but noted that the proportions vary .
It has been found that blood concentrations of
from 3 to 6 mg . per cent of the free drug are usually
sufficient for the desired chemotherapeutic effect (96)
(102) (103) .

According to Goodman (75) , sulfapyridine

can b.e detected in the blo od within one - hali' hour of
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its administration and maximum concentrations are
reached in 4 to 6 hours.
Sulfapyridine is usually given by the oral route.
In adults the initial dosage is 4 grams followed by
1 gram every four hours until the temperature has
been normal for at least 48 hours (96) (102) (103)
(104).

In infants and children, Stoessar (104)

recommends that a dose of l½ grains per pound of body
weight per day be given .

His recommendation is based

on the analysis of 169 cases so treated in which
consistent and satisfactory results were obtained.
The maximum dosage for children per day is 45 grains .
The above dosage for adults suffering from lobar
pneumonia has also been recommended by the Council on
Pharmacy and Chemistry (105).

In 1940 the Council on

Pharmacy and Chemistry advised the intravenous ihjection of sodium sulfapyridine monohydrate in "cases of
severe pneumococcic infections in which it is desired
to obtain promptly adequate blood concentrations of
sulfapyridine or in patients who, by reason of vomiting, are not obtaining proper concentrations of the
drug when sulfaphyridine is given orally, and finally,
patients in whom either the absorption of the drug is
poor or its rate of conjugation is such that adequate
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concentrations of sulfapyridine c annot be obtained in
the blood by other mean s."

Marsha 11 and Long ( 107)

in 1939 reported on the injection of a solution of
sodium sulf'apyridine mon ohydrate in thirty pat ients
with pneumo coccic infections.

A 5 per cent solution

in sterile distilled water was chosen because it would
be approximately isotonic with the blood.

The total

dose given to adult patients was 3.8 grams which was
irije cted slowly at the, rate of 5 cc. per minute.
In these thirty patients no untoward effects we re
noted in any case excep t vomiting during or immediately
after the injection.

There were no res piratory or

acute circulatory disturbances associated with the
injection, and no abnormality was observed ip the
routine examination of specimens of urine taken after
t~e injection.

A 65 kg. patient who received this

dose was found to have a total blood sulfapyridine
concentration of 6.9 mg . per cent ten minutes after
the injection was completed and 6.6 mg. per cent of
this represented unconjugated sul1'apyridine.

In

general it was found that this intravenous dose in a
65 kg . patient produced a blood concentration of 5 to
8 mg. per 100 cc. or increased an existing blood
concentration by this amount.
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Abernethy and his

associates ( 108) in a study of 135 cases of pneumococcus pneumonia found tha t intravenous administration of the sodium salt of sulfapyridine was of value
as a supp lement to the oral administr a tion of sulrap yridine.

The rap idity with which high blood concentra-

tions can be obtained makes intravenous injection of
the drug particularly useful in severly ill p a tients .
The toxic manifestations of sulf apyr idine therapy
are essentially the same as cc cur during the course
of sulfanilamide therapy.

The most frequent symptoms

are nausea and vomiting (102) (103) (104).

Pepper,

Flippin, Schwartz, and Lockwood (68) have submitted
a careful report on the toxic symptoms observed in
400 cases of p neumococcic pneumonia that were treated

with suli'apyridine.

The initial dose of the drug

was 2 grams, followed by 1 gram every four h ours until
an averag e total dose of 2 5 grams had been g iven.

The

toxic symptoms observed in their patients may give

an

approximate idea of what may be exp~cted with this
dosag e of sulfapyridine.

In about .12 per cent of the

cases re p orted, cyanosis was found either to have
appeared or increased in intensity after initiation
of sulfapyridine.

In no case, however, was cyanosis

an indication for withdrawal of the drug.
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The incidence

of other toxic reactions was as follows :

Toxic reactions

. . . . . . . . . . . . 144
212
. . .
. . . . . . 23
. . . . . . .. .. .. .. 12
. . . . . . . . . •. 2
2
.. .. .. .. .. .. .. .. .. .• 4

Nausea .
Vomiting -- troublesome
Vomiting -- severe
Dermatitis
Acute hemolytic anemia
Leukopenia
Drug fever
Psychosis

.m

Inciden ce

No .

. ..
. . .
...
. .•
...
...
. ..
. ..

• • 53 . 0%
• • 36 . 0%
• • 5 . 8~&
• , • 0 . 5%
• • 0 . 25%
• • 0. 5%
• • 0 . 5%
. • 1 . 0%

25 patients in Pepper ' s series, vomiting became

so severe ' that · the drug was discontinued, but in each
case at least· 12 g rams of the drug had been administered
and all of these patients recovered .

To

improve tolerance

to the med ication, the following measures were employed:
(1) mixing the drug v.ith water, fruit

juices or mi lk,

(2) administration of small amounts of sodium bicarbonate
or aluminum hydroxide solution after ingestion of the drug,
(3) temporary o:nission of treatment for one or two doses,
(4) the use of barbiturates and c hlora~ hydrate ,
(5) intravenous injection of solutions of sodium
chloride and dextrose , and (6) the - use of nicotinic
acid in daily dos es of 300 to 450 mg .
Hematuria also occurs during suli'apyridine therapy.
It was noted in 4

of 50 cases re p orted by Graham and

h is co-workers (lO<J) .

Smith and Needles (67) observed

the appearance of large arrow-nead shaped crystals of
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sulf'apyridine in the urine of a number of their
patients toward the end of sulfapyridine therapy .

No

evidence of renal damage was encountered except in one
patient .

In this case anuria developed after 8 grams

of the drug had been administered.

Pepper and others

( 68) emphasized the de sir a bi li ty of. avoiding de hyd ra ti on since it might lead to concentration of th·e
urine sufficient to cause crystallization and the
development of sulfapyridine concretions within the
urinary tr&ct .

If hematuria or anuria occurs , the drug

should be discontinued promptly .

Long (110) noted that

hematuria with or without signs of renal failure hs. s
been observed in patients who were receiving sulii.pyri dine .

It appears to be assoc i ated with the formation

of acetylsulrapyridine calcul i in the renal tubules
or pel ves .
Sul1'apyridine therapy in pneumonia produces a
marked clinical reaction .

The temperature of the

patient declines repidly and usually becomes normal
within 24 hours ( 57) ( 67)

( 102) ( 103)

( 104) .

Of

forty-two patients treated with sulfapyridine , Garvin
(103 ) reports that 20 . 6 per cent had a normal t empera -

ture within 24 hours while the remaining number of
patients had a normal temper at ure in 48 to 72 hours .
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All cases that res p ond to th e drug show clinical
improvement very ra p idly as evidenced by the ra p id
fall in temper a ture and pulse · rate and g eneral
improvement in t he patients' cond ition .

Resolution

of the p neumonic process usually begins about the
t h ird or fourth d a y and takes severa l days for
completion .

In the opinion of Long (57) it is

advisable to continue treatment with the drug until
r e solution is well established , otherwise a re c urren c e
of the infection may follow .

Sul fathiaz o l e

Sulfathiazole was synt~esized as the result
of a s e arch for less toxic chemotherapeuti c a g ents .
Its chief advantag es , in comparison with sulfapyridine ,
are believed to be (1 ) more u n iform abso r ption ,

(2 )

less conjuga tion after absorptio n so that a higher
p roportion of the total drug in the body fluids is
chemotherapeutically active , and (3) less tendency
to cause serious nausea or provoke vomiting .

Results

of sulfathiazole and sodium su11·athiazole therapy in
lob &r pneumonia are as good as , if not better than,
those re p orted for s u lfapyridine .
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The mortality

figures for sulfathiazole treated patients appear to
be somewhat lower than those for sulfapyridine treated
cases.
Chemically, sulfathiazole is the thiazole ana lpgue
of sulfapyridine.

The structural formula of sulfa...~

0 H

thiazole is represented as follows: H 2 1 ~ - ~ - N -

<:=J

It differs from sulfanilamide in that one hydrogen
atom of the amide group is replaced by the thiazole
group .
Long, Haviland, Edwards , and Bliss (110) found
that sulfathiazole is readily absorbed and, in most
instances, ra p idly excreted by humans.

The percentage

conjugation of the drug in tissue was about the same
as had been noted for sulfanilamide.

In the urine,

definitely less sulfathiazole was acetylated than is
the case with sulfapyridine .

Because of rapid absorp -

tion and excretion of sulfathiazole, it was more difficult to maintain adequate blood concentrations of
this drug than with sulfanilamide and sulfapyridine.
Reinhold, Flippin, and Schwartz (111) administered
3 grams of sulfathiazole to each of six subjects and
subsequently made blood concentration determinations
of the drug .

Within one hour after administration the

concentration of free sulfathiazole in the blood of
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three of the six individuals reached or exceeded 4 . 5
mg . per cent .

In five of the six persons studied the

blood level reached a max imum at the end of two hours
and concentrations remained above 4 mg . per cent for
4 to 6 hours .

In the sixth patient ability to absorb

the drug was apparently impaired and a max imum was not
reached until eight hours had elapsed.

These authors

also follc:wed the blood sulfathiazole concentrations of
patients who received initial doses of 3 gram s of
sulfathiazole, and thereafter were g iven 1 gram every
four hours over periods varying from one to twelve days .
This dosage maintained an averag e concentration of 5
mg . per cent free sulfathiazole , although the individual
results varied from 1 . 2 to 19 mg . pe r 100 cc . of blood .
Strauss and h is associates (112) found that sulfa thiaz ole was very poorly absorbed f'r oe1 the rectum and
a lso noted that it was p resent re gu l arly in the spinal
fluid in about one - t h ird the concen tr a tion found in the
blood .
Long (113) in 1940 ga ve a preliminary re p ort on
the t hiazo le derivates of sulfa n ilamide .

In g eneral ,

it was indicated, that sulfathiazole is les s toxi c
than s u lfapyridine.

In his opinion sulfathiazole

is of about the same effectiveness in pneumococcic
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pneumonia as sulfapyridine.

Long found that the toxic

effects of sulfathiazole were similar in nature to
those of sulfapyridine though nausea arrl vomiting were
definitely less of a problem .
Flippin, Schwartz , and Rose (114) used sulfathiazole
in treating 100 patients with typed pneumoco cc al
pneumonia .
mouth .

An initial dose of 3 gra~s was gi ven by

This amount was repeated in four hours , afte r

v;hich 1 gram was administered every four hours .

In

several extremely ill patients treatment was begun
with 3 gr am doses of sulfathiazole each at tour-hour
intervals .

This dosage ma intained an average of 5

mg . per cent blood concentrations of free sulfathiazole .
Treatmen t was continued until the temperature rema ined
normal for 48 hours and there was evidence of clinical
improvement.

In general th e total do sa ge was 25 to

40 grams depending upon the physi c al and laboratory
findings in each case .
cent.

The mortality rate was l:c per

Howe ver, after making allowances for patients

¼ho were hospitalized for period s less than 24 hou rs,
the corrected mortality was computed as 7 . 4 per cent .
In a comparable series of pa tients 1reated with sulf'apyridine, the corrected mortality was 11.4 per cent.
Average ho spital days were about the same for the two
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drugs,

and these investigators remark that the severity

and frequency of nausea and vomiting in the sulfathiazole-treated patients was less than in those
patients receiving sul1'apyridine .
Abernethy (115) reported the use of sulfatniazole
in 35 cases of pneumonia , 31 of which vere pneumococcal ,
the other 4 presumably being due to other organisms .
Only 2 deaths occurred among the thirty-one treated
patients, a mortality rate of 6 . 4 per cent .

The dosage

used at the beginning of the study consisted of an
initial amount of 4 gram followed by 1 gram doses at
4 hour intervals day and night until the temperature
v'as normal ror 48 hours.

Subsequently, the dosage

was gradual ly reduced, although it was continued until
convalesence wa s well established .

Garvin , (116) in

the treatment of pneumocoocic pneumonia , used an initial
dose of 4 grams by mouth followed by 2 gram every four
hou rs until clinical improvement occurred .

Then 1 gram

was given every four hours until the temperature\, as
normal for two or three days and clinical improvement
~as definite .

This dose produced an average level of

5.8 mg. of free sulrathiazole fB r 100 cc. of blood .
Scott and Jones (11~) used sulfat h iazole in the
treatment of 167 cases of pneumonia in children.
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The

dosage was based upon body weight .

The. sulf'athiazole

tablets were usually crushed to a pov.der and given
v;i th milk or fruit juices or administered whole to the
older children .

In all but a few cases a daily dose

of 1 grain per pound of body weight was used .

Usually

one-fourth to one-half of this amount was given initially
and then one-eighth of the daily dose was administered
every three hours day and night , the patients being
awakened if necessary.

In nearly every case the drug

seemed to precipitate an early crisis .
for the better occurred v, it hin 12 hours;

Usually a change
the fever and

toxicity lessened, dyspnea was relieved, and irr many
cases fever disappeared entirely ln 24 hours .

Arter 48

hours few of the patients had fever, and after 72 hours
only nineteen of 158 patients who were successfully
treated had fever .

Coincident with the fall in tem-

perature the child ' s appetite, activity , and responsive ness improved .

Usually physical signs in the lungs

improved with deferesence , but this was not always the
case .

Five of the patients died .

Two of these were

admitted in extremis and received very little of the
drug .

Toxic effects were largely gastro-intestinal ,

consisting of vomiting and diarrhea .
The toxic reactions resulting from sulfathiazole
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therapy are , by and large , similar to those previously
noted following the use of sulfapyridine .

Long {118 )

listed the follovling ob serva ti ons concerning possible
toxic manifestations after the use of sulfathiazole :
Toxic Reactions

Incidence

Nausea and vomiting • • • • • • • • Uncommon
Dizziness • • • • • • . . • • • • • • Uncommon
Psychosis
• . • • • • • • • • • • • Rare
Neuritis
• . . • • . • . . . • • • Rare
Cyanosis
• • • • • • • • • . • • • Uncommon
Fever
• • • • • • • • • • • • • 10 per cent
Rash
• • • • . • •• • • • • • 5 per cent
Hepatitis
. . • • • • • • • • • • • Rare
Leukopenia with granulocytopenia • • 1 . 6 per cent
Acute agranulocytosis • • . . . • • Rare
Acute hemolytic anemia • • • • • • • Very Rare
Hem~turia . • . • • • • • • • • • • 2 . 5 per cent
Injection of scleras and conjunctivas . 4 . 0 per cent
Ocular and auditory disturbances • • Very rare
Jaundice
• • • • • . • • • . • . • Wi tJn. acute hemo lytic anemia or
hepatitis
Gastro-intestinal disturbances • • • Very ra re
Painful joints . • •• • • • • • • • Reported with rash
Stoma~i tis
• • . • • • • • • · • • • • Reported
It was considered best to stop the drug and force fluids
when any severe toxic effects were manifested . ,

In a

series of 169 patients treated with sulfathiazole, Volini,
Levitt and O'Neil (119) noted seven who developed a
rash .

In four of these people the manifestations ap-

peared after five days' use of the drug .

One person

showed a maculopapular rash within twenty- four hours
after resumption of the drug when it had bee n discontinued for six days .

This suggested sensitization .
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One of

the seven rashes was urticarial in type , three were
maculo - p e.pular , and three definitely nodular , one of
the latter group being complicated by a purpuric
lesion .

Conjunctivitis was also present in four of

the seven cases.

Only one patient with severe

conjunctivitis unassociated with cutaneous eruption
was encountered .

After cessation of the drug the

conjunctivitis cleared rapidl y and no permanent
chan ge s were noted.

Immediate cessation of the drug

is indicated in such cases .
~einstein and Domm (120 ) reported a fatal case
of exfoliative dermatitis developing after administra tion of 15 grams of sulfathiazole .

This patient had

developed a dermatitis in 1929 following intravenous
therapy, presumably from arsphenamine .

These authors

concluded that the safest procedure is to withdraw
the drug and force fluids at the e a rliest sign of
toxicity as manifested by a skin rash .
Arnett (121) described a case of pneumonia which
developed hematuria and oliguria after 14 grams of
sulfathiazole had been taken in forty- eight hours.
Sulf'athiazole was stopped and 900 cc . of 5 per cent
dextrose in physiological solution of sodium chloride
were administered by vein.

On the following day the
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lumbar pain had subsided, the urine was slightly
less bloody, although it still co ntained some blood
cells and crystals, and the patient's general condition was improved.
Schwartz, Flippin, Reinhold and Domm recommend
that the urinary output be kept at 1,200 cc. daily as
a means of preventing crystals of sulfathiazole in the
urine.

They also observed that pat ients who took

sodium bicarbonate in an amount equal to the dose of
sulfathiazole had a lower incidence of crystals cf

the

drug in the urine than those who took the drug without alkali.

Crystals were found more frequently and

in greater numbers in acid urine.
Kennedy and Finland (123) reported a case of acute
a g ranulocytosis be g inning toward the end of the third .
week of treatment • vd th sulfathiazole.

The authors re-

commended close observation of the blood in patients
under prolonged therapy with sulfonamides.

Lederer and

Rosenblatt (124) in Ma y, 1942 reported four cases of
death attributed to sulfathiazole therapy .

Autopsy

findin g s revealed necrotic visceral lesions in all cases.
These authors emphasize ' the importance of judicious
use of this drug .
Long and his associates (110) advocate that a
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hemoglobin determination and a total white blood cell
count be made prior to initiating therapy with the
sulfonamide drugs .

These should be repeated at two

day intervals thereafter .

The urine should be ex-

amined, especially for red blood cells, at least, every
other day .

If possible, the following daily observa-

tions are recommended:

(1) temperature, (2) examine

the scleras for jaundice, (3) evidence of cutaneous
rash,

and (4) the patient questioned regarding head-

ache or malaise because these may be early symptoms
of an imminent toxic reaction .

Sulfadiazine

Sulfadiazine is the most recent member of the
sulfonamide group to be given considerabJe
trial in the treatment of pneumonia .

clinical

This drug has

certain definite advantages over its older analogues ,
sulfathiazole and sulfapyridine .

It combines clinical

effectiveness with extremely low toxicity .

Its effect-

iveness in the treatment of pneumococcic pneumonia has
been repeatedly demonstrated (17) (92)

(125) and it seems

to be the drug of choice in this disease .
Roblin and his associates (73) have shown that
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sulfadiazine is the pyrimidine analogue of sulfa- .
pyridine and could logically be named "sulfapyrimidine 11
However, this would give riBe to considerable confusion
\t\i. th sulfapyridine, and since the pyrimidine is als o a

diazine ring it seemed more practical to name this new
drug sulfadiazine.

This substance is a white crystal-

line material and is soluble to the extent of 12 mg .
per cent in water at

.

37°c.

The structural formula is

N- -CH
NH 2- ~ - S 02- NH...e'
~H .
~

N===CH

Sulfadiazine has been shown to possess the following principal advantages over the other sulfonamides .,
(17)

(92) (125)

of all kinds;

(126); (1) lower incidence of toxicity

(2) effective blood concentrations are

read i ly reached and maintained with oral administra tion;

(3) a relatively low proportion of acetylated

sulfadiazine is iormed in the blood ; (4) decline of
the sulfadiazine blood level is gradual once the drug
has been discontinued;

(5) ready penetration of the

drug into pleural , peritoneal, and cerebrospinal
fluids; and (6) ready solubility of acetyl sulfadiazine in the urine, a factor which reduces the
possibility of severe kidney damage from its use.
It has been found that sulfadiazine a p pears to
be more active a g ainst experimental pneumococcal infections in mice than sulfanilamide, sulfapyridine, or
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•

suifathiazole (73)

(126).

Feinstone and his co-workers (126) have reported
an exhaustive sb; dy of the che mothe ra peut ic activity,
absorption, and toxicity of sulfadiazine.

They

observed that the blood concentration resulting from
given doses of sulfadiazine wa s about four times- as
high in monkeys as that occurring with similar doses
of sulfapyridine.

Mice maintained on diets contain-

ing 0.125 to 2 pe r cent of the various compounds showed
blood concentrations_four or five times higher than
those obtained with sulfanilamide, sulfapyridine, or
sulfathiazole at the same percentage of drug intake.
In the dog absorption of sulfadiazine following a
single dose was not markedly different fro m that of
sulfapyridine.

Rabbits showed a g reat deal of individ-

ual variation, but on the whole the blood concentrations of free sulfadiazine were higher than those obtained from similar doses of sulfapyridine, and the
amount of acetylated sulfadiazine was ·generally less.
It was found by these same · workers that the
absorption of sulfadiazine by mice following single
oral doses was rap id, a.nd concentrations of the drug
were maintained in the blood stream for more than 20
hours.

Monkeys absorbed oral doses of sul1'adiazine to

produce a high blood concentration within one hour, but
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a peak might not be reached until four or more hour s
had elapsed .

The blood stream was not entirely free

of the drug thirty hours later .

\,hen sulfapyridine was

given to monkeys , 50 per cent of the blood concentration was in acetyl form, but less than 10 per cent of
sulfadiazene was found to be acetylated when it was
similarly administered .
The acute toxicity level of sulfadiazine for
mice was a blood concentration of about 175 to 200 mg .
per cent .

Similar levels for sulfathiazole ' and

sulfapyridine were 80 and 65 mg . per 100 cc . respectively .
In chronic toxicity experiments , it was further ob served that sulfadiazine produced less tissue damage
for a g iven blood concentration in monkeys than sulfathiazole or sulfapyridine .

This was attributed partly

to the higher solubility of acetyl sulfadiazine in the
urine when compared with acetylated sulfapyridine and
sulfathiazole and also to the fact that sulfadiazine
is not conjuga ted to the Eame extent as sulfapyridine .
The investigations in animals carried out by
Feinstone and his workers indicate that : (1) the blood
levels of sulfadiazine were highe r than those of the
other sulfona"llide drugs because of differences in ab sorption and excretion; (2) the degree of acetylation
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of sulfadiazine v:as less than of sulfapyridine;

(3) the

acute and chronic toxicity was lower than that of sulfapyridine and sulfathiazole;

(4) sulfadiazine had a high

therapeutic activity against pnewn8coccal, streRtococcal, staphylococcal, and Friedlander's bacillus
infections in mice .
The behavior of sull'adiazine in man has beeh re:ported by a number of investigators and experimenta~
advantages have been borne out by clinical· tr_ial ( 125 )
(126)

(127) (128) (129) (130) .

Plummer and Ensworth

( 127) stated that sulf'adiazi ne was ra;,idly absorbed
into the blood stream of man and that comparatively
high levels of total drug were reached.

They found

that the prop or ti on cf conjugated sulfadiazine in the
blood was small, and that the b lood leve l falls rather
slowly after the drug is discontinued .
is e~creted · by the kidneys .

Most of the drug

In e~ght persons who were

g iven a total of 7 to 16 grams of sulfadiazene , the
only toxic reaction :.-J.oted was a morbilLi form rash in
one instance .
Reinhold and his co-workers ( 128) in 1941 reported
the results of their investigations on the fate of
sulfadiazine in a group of human beings .

Two experiments ,

one dealing with the fate of a single dose and the o t her
with response to multiple doses, were reported .
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The drug

was readily abs~rbed from the gastro-intestinal tract
of most of the individuals .

It was not excreted as

readily as sulfathiazole and disappeared slowly from
the blood stream , indicating that smaller quantities
of sulfadiazine would probably be required.to maintain a given blood level .

As regards acetylated

sulfadiazine , the authors did not find any difference
from the concentrations previously observed in studies
of

sulfathiazole .

The concentrations of sulfadiazine

in peritoneal and pleural fluids approximated those in
blood.

In cerebrospinal fluid , concentrations were

found to average 50 per cent of the blood level .

In

their limited experience sulfadiazene exhlbited at
least no greater toxicity than other.similar drugs used
in treating pneumonia.
Sadusk and Tredway (129) found that sulfadiazine
was readily absorbed by man in most cases but not
rapidly ex c reted, and that it diffused readily into
pleural and ascitic fluid but at a somewhat slower rate
into the cerebrospinal fluid .

Acetylation of sulfa-

diazine in the blood rarely exceeded 20 per cent, but
was somewhat higher in urine though rarely sufficient
to cause precipitation of crystals.
experience suggested a low toxicity .
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Their limited

Peterson, Strauss, Tay lor and Finland (130) also
carried out an investigation of the absorption , excre tion, and distribution of sulfadiazine in man , obtaining
similar results .

Higher blood levels were reached

and were more sustained with sulfadiazine than with
sulfanilamide ,

sulfapyridine, and sulfathiazole .

Conjugation in the b lood was usually slight and there
was no tendency of the conjugated drug to be retained.
Its penetration into the spinal fluid resembled sulfaanilamide ani sulfapyridine ..

Sulfadiazi ne or the

sodium salt was not absorbed to any appreciable extent
after rectal administration .

Nausea , vomiting , and

mental depression were notably absent in pat ients
treated with sulfadiazine , and other serious toxic
effects were QOt encountered~
Long ( 118) ob served that administration of single
doses of sulfadiazine produced peak blood concentrations
between the sixth and eighth hours .

The drug was

excreted mainly by the kidneys , the rate of excretion
being slower than that of sulfanilamide ,
or sulfapyridine .

sulfathiazole ,

He also observed that free and

conjugated fractions of sulfadiazine seemed to be mor e
readily excret ed by a damaged kidney than would ha ve
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been expected with sulfapyridine or sulfathiazole.
The reduction in mortality in pneu.~onia as a
result of sulfadiazine thera py compares favorably with
that from sulf apyridine or sulfa t h iazole.

In the

tre&tment of pneumococcic pneumonia, Flippin and his
associates (131) used s u lfadiazene in 100 adult
patients and sulfathiazole in a similar series of 100
cases.

There were 11 deaths in the sulfadiazine series,

five occurring ln persons hospitalized for less than 24
hours .

The corrected mortality rate for this group

was 6 . 3 per cent.

In the sulfathiazo le series the

aut h ors re po rted 17 deaths, eight in patients hospitalized for less than 24 hours .

The corrected mortality

for this group t hus being 10.8 per cent.

Sulfadiazene

tended to lowe r the temper ature somewhat more rap idly
than sulfathiazole.
diazine was employed :

The following dosage with sulfaan initial dose of 3 grams was

followed by 1 gram every four hours unless signs of
severe toxicity developed .

Treatment was continued

until the temperature re mained normal for 48 hours ,
along with evidence of clinical improvement.

More

recently (1943) Flippin , Schwartz, and Domm (125)
advocate an initial oral dose of 3 g rams of sulfadiazine
followed by 1 gram every 6 hours uhtil clinical improve-
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ment is shown and the temperature has remained
normal for 48 hours.
In a series of 200 pneumococcic pneumonia patients
treated with sulfadiazine, Flippin and his associates
(17) reported 24 deaths or 12 per cent mortality .

If

the 8 deaths which occurred within 24 hours are excluded , a corrected morta l ity rate of 8 . 3 per cent is
obtained .

20 . 5 per cent of patients gave positive

blood cultures with a mortality of 34 . 1 per cent .
Mortality rate corrected for this group was 22 . 8 per
cent .

The mortality rate for oral administrat ion was

comparable to that obtained with sodium sulfadiazine
given by vein .

Type specific serum was used in addi -

tion to sulfadiazine in 24 patients who were considered
to be extremely ill .

To prevent inhibition of growth

of the pneumococcus by the drug, sulfadiazine containing specimens of blood were cultured in a medium containing para- aminobenzoic acid .

The work of Woods

(78) has demonstrated that para- amino - benzoic acid can
neutralize the inhibitory action of the sulfonamide
drugs .
In the report of Flippin , et al ., a critical fall
in temperature occurred in 69 . 9 per cent of patients in
24 hours and in 84 . 1 per cent during the first 48 hours
of treatment .

The temperature fell and remained within
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normal range in 17 . 6 per cent of pati ents within 24 ho.urs
and in 55 . 1 within 48 hours .

Patients receiving sodium

sulfadiazine intravenously showed a similar incide nce
of critical fall in temperature but regained a normal
temperature more slowly.

These authors used an ini -

tial oral dosage of 3 grams followed by 1 gram every
6 hours until the temperature re ma ined normal for 48
hours and the patient showed clinical evidence of
improvement .

It was possible to adhere to 6 hour

dosage because of slow excretion of the drug by the
k idneys.

A 5 per cent solution of sodium sulfadiazene

was given intravenously when a rap id elevat ion of the
blood level of the drug was desired or when oral administration was impracticable .

An initial 3 gram dose

was followed by 2 grams every 12 hours until clinical
improvement was shown and the te mp erature was normal
for 48 hours .
Ensworth, Kalkstein, Barefoot and Liebmann (92)
reported a s e ries of 239 patients with pneumococcus
pneumonia tr eated with sulfadiazine at the Bellevue
Ho spital during the winter of 1940-41.

The sulfadla-

zene was 5 iven orally in most of the cases and the usual
dosag e was 2 g rams initially followed by 1 gram every
4 hours .

The aut h ors re po rted a case fatality rate of
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10 . 9 per cent .

If 24 hour dea:;hs were excluded, the

corrected mortality was 7 . 8 per cent .

The incidence

of toxic reactions and the number of c omplica ti ons were
found to be low .
Flippin, Schwartz, and Domr.i. ( 125 ) in January , 1943
presented a report based on experience with 1,635 cases
of pneumococcic pneumonia of adults treated with sulfapyridine, sulfathiazole or sulfadiazine in the medical
wards of the Philadelphia General Hospital between
August 1938 and April 1942 .

Sulfapyridine, sulfathiazole

and sulfadiazine were comparable in effectiveness as
judged by the mortality rates of 9 . 7 , 12 . 1, and 10 . 3
per cent for the three therapeutic groups respectively .
There were 733 cases treated with sulfapyridine , 447
cases with sulfathiazoJB , and 455 cases treated with
sulfadiazine .

The averaged mortality rate for these

series of cases was 10 . 6 per cent .

During the five

years prior to the use of the sulfonamide drugs the
mortality rate in 1 , 904 cases of pneumococcic pneumonia
ob served at the Philadelphia General Hoe pi tal w as 40 . 1
per cent .

These figures certainly indicate the thera -

peutic value and effectiveness of the sulfonamide drugs .
These authors conclude that sulfadiazine is the drug of
choice in the treatment of pneumonia at the present time .
These conclusions are based on (1 ) the therapeutic
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effectiveness of the drug as evidenced by the morta l ity
rate;

(2 ) the low incidence of complicat i ons and toxic

manifestations ; and (3) the pharmacologic behavio r of
the drug in man ; i . e ., high blood con c entrations , low
degree of acetylation in blood and ur i ne , and ready
solubility of acetyl sul fadiazine in the u r ine .

It was

found that best results with sulfadiazine were obtaine d
when treatment was started early in the disease .

If

the drug was started after the f ir st 48 hour s of i l lne s s ,
there was a definite increase int he mortality rate and
incidence of complications .

In order to control drug

toxicity , it is recommended that alkalis be used routinely
and the fluid intake be abundant to maintain an adequate
urinary output of at least 1 , 200 cc . in-each 24 hour
period .
In the 455 cases treated with sulfadiazine, the
following toxic reactions were noted :
Toxic Reactions

Incidence

Vomit i ng • • • • • • • • . • • • • •
3 .1
Hematuria : Microscopic • • . • . • •
4.4
Gross . . • • • • • • • •
0.2
Loin pain . • • •• • • • • • • • • •
0
Renal calculi • • • • • • • • • • • •
0
Anuria
•••••••••••••• 0
Dermatites
•• • • • • • • • . • • • 1 . 1
Conjunctivitis . • • • • • • • • • • • 0
Eoiscler i tis . • • • • • • • • • • • 0 . 2
Acute hemo l ytic anemia
••••••• 0
Leukp a.nia • • • •. • • • • • • • • • • . 2 . 0
Neutropenia • • • • • • • • • • • • • • O
Fever ?
• • • • • • • • • • • • • 2.2
Psychosis
••••.•••••••• 5 . 5
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Schulte, Shidler , and Niebauer (132) in May 1 942
reported one case of urinary suppression following
sulfadiazene therapy.

In a review of the literature

they found a similar case reported but once.

The

average d oses of the drug wa s used in both cases.
Althoug h this complication is very rare, it is quite
serious.

The signs and symptoms of beginning renal

failure in the opinion of these authors are miscroscopi c
and gross hematuria , cr ystalluria , abdominal and flank
pain , decreased u rinar y output, and nausea and vomiting.

Treatment of this condition consists of forcing

fluids and alkalizing the urine .

If the urinary out-

put decreases considerably , then cystoscopy, uretera l
catheterization and lavage are immediately indicated
with continuous urinary drainage b ; means of an indwelling catheter.

Sulfa.:e.xrazine

Sulfap yrazine is a new sulfonamide compound whi ch
is being investigated in the treatment of pneumo coccic
pneumonia.

This drug is the para -isomer of sulfa-

diazine and wa s synthesized in 1941 by Ellingson (133).

N

The structural formula of sulfapyraz ine is H2 NQs(Q NH

.

N
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The preliminary investigations of Ruegsegger and his
associates (74) indicate that the toxicity of this
rompound in man is rel ative ly low and its antipneumococcal activity is high .

The work of Hamburge r and

his group ( 134) ba ve shown that sulfapyrazine is slowly
absorbed from the gastro -intestinal tract and is
excreted more slowly by the kidney than is sulfadiazine,
sulfapyridine or sulfathlazole.

It was also found that

a cetylsulfapyrazine is more soluble in wate r or urine
tban sulfapyrazine.

The drug enters the cerebrosp inal

fluid slowly, reaching concentrations of about 50 per
cent of that of the blood 12 hours after an intravenous injection.

It was noted that concentrations of the

drug in most body fluids approach or exceed the concentrations in the blood.

Orally administered sulfa-

pyrazine was observed to yield lower blood levels on
a given dosage than does sulfadiazine.

Schmidt and his

co-workers (135) investigated the antipneumococcal
activity of sulfapyrazine by in vitro and mouse
curative tests.

They found that milligram for milligram

sulfapyrazine is considerably more effective than
sulfadiazine.

It is quite likely that sulfapyrazine will

be the drug of c hoi ce in the treatment of pneumoco ccal
pnewnonia within the present year.

The clinical investi-

gations needed to determine its efficacy and establish its
p restige are certain to be carried out in the near future.
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Summarz and Conclusions

Since 1880 there has been a constant search for
a specific agent which would a ct d ir ectly against the
pneumo coccus organism .

However , it was not until 1935

that such an a ge nt, in the form of sulfanilamide, was
discovered.

Sulfanilamide and its related compounds

were qui ck ly heralded as a pane cea for the tr eatment
of pneumonia and the remarkable reduction in mortality
for this disease has s uppor t ed the great enthusiasm
for these d r ugs .

The sulfonamides have been sh ovm

to be effective in all types of pneumococc us pneumonia
in man and in experimental animals with pneumon ias
due to the streptococcus, staphylococcus and Friedlander bacillus (75).

In the eo -c alled virus pneumonia

which has been present in recent years , the sulfonamides
have proved to be ineffective (21) .

At the present time,

the only me ans we have of comba tin g virus pneumonitis
is supportive therapy.

There have been no reported

studies desc r ibing the use of x-ray therapy in virus
pneumonias .

How e v er , it seems to ne ,

that this form

of the ra py , especially in severe cases , is worth a
clinical trial .
Since the beginning of this century, ther e ha ve been
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four advances in the treatment of pneumonia .
of their oo currence , they are :

In order

( 1) serum therapy

(2) oxygen therapy (3) chemotherapy and (4) roent gen
therapy .

Serum came into widespread use about 1 910 ,

and was the first specific weapon to be used against
the pneurnococcus organism .

Vath the use of this

agent , the fatality rate for pneumoccus pneumonia of
all types except type III was reduced 40 to 50 per cent .
Oxygen, &s a therapeutic measure for the relief of
cyano sis and dyspnea, has been universally used since
the first world war .

This was the second advance in

pneumonia therapy tn~t helped to lower the fatality
rate .

The greatest advance in the treatment of pneumonia

dates from 1936 when the sulfonamides first became
available to the medi c al profession .

The rapidity with

v.hich these drugs v,ere accepted and universally used
has broken all medical precedent.

This development is

the first innov i::.tion in the history of medicine to be
so readily and complet ely accepted by the entire
profession .

The few years of clinical trial wit h the

sulfonamides ,have proven their great value .

The

mortality rate in pneumonia cases of all types has
been lowered to approximately 10 per cent ty the simple
use of these drugs .

The fourth advance in the treatment

_Qi:;_

of pneumonia has been the roentgen ray.

Recently it

has been shown that; x-ray therapy is cf undoubted value
in treating pneumococcic pneumonia cases that do not
respond to the sulfonamides and therefore roentgen
therapy should prove to be a valuable adjunct to chemotherapy .
The review of the literature on the treatment of
pnelL~onia v..b.ich has been made in the writing of thi s
thesis brings out certain results and observations
that can well be set down as the conclusions to be
reached following a study of the present day management
of

pneumonia .
1.

These conclusions are herewith presented :

Sulfonamide therapy is the treatment of choice

in all cases of pneumonia .
2.

Sulfadiazine , at the present time , is the drug

of choi c e in the treatment of pneumonia .
3.

The fo l lowing precautions should be observed

during active treatment vJl.. th sulfonamide drugs :

(a )

insure adequate fluid intake ; (b ) give alkalis wi th the
drug , and ( c) check the blood picture every t1/\0 days .
4.

Sodium sulfadiazi ne can be used intravenously

when rapid elevation of the b l ood level is desirable or
when ora 1 ad.mini stra.t i on of the drug is
5.

not feasible .

Supportive measures in pneumonia are stil l
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important and should not be neglected .
6.

X-ray therapy is a potential valuable adjunct

to chemotherapy.
7.

Serum should be used in addition to the sul-

fonamides when the expected clinical respons€ is not
evident within 24 to 48 hours .
8.

Chenotherapy possesses the following advantages

or er serum therapy:

(a) the drugs are less expensive;

(b) they are eas'ier to administer; (c) the danger from
serum reactions is removed;

(d) the drugs are effective

against several species and types of bacteria; and (e )
the drugs given better results as shown by the mortality
rates.
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